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CHAPTER 1 
Introduction and outline of thesis 
Chapter I 
Tumor angiogenesis 
Angiogenesis is the outgrowth of new blood vessels from the préexistent 
vasculature This process is involved in a wide range of biological and 
pathological processes, including embryogenesis, endometrial proliferation, 
wound healing, retinal neovascularization, and solid tumor growth ' 2 The 
formation of new, functional microvessels during angiogenesis is dependent 
on multiple, temporally and spatially coordinated steps, including 
production and release of angiogenic factors, directional migration and 
proliferation of microvascular cells, proteolytic degradation of extracellular 
matrix (ECM) barriers, and the composition of new vessels 37 
Like normal cells in most human tissues, tumor cells are dependent on the 
vasculature for their supply of oxygen and nutrients and removal of waste 
products Solid tumors need to induce angiogenesis to meet the metabolic 
demands of a growing population of tumor cells Already in 1971 Folkman 
hypothesized that anti-angiogenic treatment is a potential therapy for these 
tumors 2 8 9 In several tumors, angiogenesis not only seems to allow tumor 
growth, but also to increase the probability of tumor cells to enter the 
circulation and metastasize 10 Given this critical role for angiogenesis in 
the enlargement, and possibly metastatic potential, of solid tumors, it is 
now generally accepted that the angiogenic process is a logical target for 
new anti-cancer therapies " 
Based on new insights into the mechanisms of angiogenesis, novel 
therapeutic approaches targeting this process have been developed " 13 
Numerous compounds display inhibition of angiogenesis under 
experimental conditions by interference with one or more of the steps in 
the angiogenic process mentioned above 1213 Some anti-angiogenic agents 
are now being studied in phase 1 and 2 clinical trials for solid tumors like 
breast, colon, lung, and prostate cancer " 
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Human brain tumors 
In the human brain and its meninges a wide variety of primary and 
secondary tumors can be encountered The primary tumors are composed 
of neoplastic cells derived from the normal brain (e g gliomas from glial 
cells) or its coverings (meningiomas from memngothehal cells), while the 
secondary tumors are metastases, usually of carcinomas (detailed 
information about clinical and pathological aspects of brain tumors can be 
found in '415) 
The most common primary brain tumors in adults are gliomas, including 
neoplasms displaying astrocytic, Oligodendroglia!, and ependymal 
differentiation The most frequent gliomas are astrocytic tumors that show 
diffuse infiltrative growth in the préexistent brain tissue On the basis of 
four histopathological criteria (nuclear atypia, mitotic activity, 
microvascular proliferation (MVP), and necrosis) these diffuse astrocytic 
neoplasms can be divided arbitrarily into three groups of increasing 
malignancy astrocytoma (A), anaplastic astrocytoma (AA), and 
glioblastoma multiforme (GBM) '5 '7 Generally oligodendrogliomas also 
show diffuse infiltration in the préexistent brain tissue Examples of brain 
tumors with an expanding rather than infiltrative growth pattern are 
meningiomas, ependymomas, and metastatic carcinomas 15 
Due to the infiltrative growth pattern of diffuse astrocytic neoplasms, 
complete surgical resection is often impossible, and eradicating tumor cells 
by chemotherapy and/or radiotherapy without damaging the involved brain 
parenchyma has been difficult to achieve The prognosis for patients with 
these tumors thus remains poor The median survival of patients with 
GBMs is less than 1 year and of patients with AAs less than 3 years l6 
Because GBMs are not amenable to conventional therapies and frequently 
show a remarkably florid, often glomeruloid MVP '516, these tumors have 
become an especially strong candidate for anti-angiogenic treatment 1821 
Expectations for success were strengthened by animal studies in which the 
growth of glioma xenografts could indeed be inhibited by anti-angiogenic 
therapy 22 и 
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Outline of thesis 
Most studies on the pathogenesis of brain tumor angiogenesis concentrated 
on the role of angiogenic factors and their receptors 2628 The studies 
presented in this thesis focus on quantification of the angiogenic reactions 
in diffuse astrocytic brain tumors, the identification of the cellular 
components of the newly formed microvessels in these tumors, and the 
potential role of microvascular ECM-binding integrins and complementary 
ECM components in the pathogenesis of glomeruloid MVP in GBMs 
Further clarification of the angiogenic process in human astrocytic brain 
tumors may put the expectations about the value of anti-angiogenic therapy 
for human brain tumors into perspective of the anatomic realities of the 
vasculature in these tumors and may offer additional targets for 
interference with (tumor) angiogenesis in general29 
The presence of glomeruloid MVP in GBMs gives the impression of a 
highly vascularized tumor However, the aberrant architecture of 
glomeruloid MVP and its paradoxical coexistence with (sometimes 
extensive) foci of necrosis suggest that its contribution to the viability of 
the tumor tissue may be limited 213031 The efficacy of anti-angiogenic 
therapy for GBMs may rather be determined by the degree of classic 
angiogenesis with the formation of delicate microvascular sprouts The 
extent of such classic angiogenesis in diffuse astrocytic tumors is not well 
established In order to differentially quantify the microvascular changes in 
these neoplasms, we developed a method for computer-assisted image 
analysis of the specifically visualized microvasculature in glial tissue This 
method, described in chapter 2, is first used to assess four microvascular 
parameters (number, area, perimeter, and diameter), and the cellulanty of 
the extravascular tissue in histological whole tumor sections of seven 
untreated, supratentonal human GBMs obtained by autopsy In this study, 
the parameters in GBMs are compared with those in histologically normal 
cerebral cortex and white matter of the same patients 
In the study described in chapter 3 a similar method is applied to quantify 
the microvascular changes in biopsies of supratentonal diffuse astrocytic 
neoplasms with increasing grade of malignancy In addition to the four 
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microvascular parameters and the tissue cellulanty, the MIB-1 labelling 
index is assessed in 13 As, 14 AAs, and 20 GBMs, and the correlator 
between the different parameters within the tumors is investigated 
Florid MVP in GBMs is characterized by multilayered proliferation of 
swollen microvascular cells in the vessel wall '5 '6 The most prominent 
form of this MVP was called "glomeruloid" MVP because of the formation 
of coiled, glomerulus-hke capillary loops 32 This MVP has long been 
considered as proliferation of endothelial cells (ECs), as is apparent in the 
common designation "endothelial proliferation" 33 In chapter 4 the cellular 
components of the newly formed microvessels m human glial brain tumors, 
intracerebral metastatic carcinomas, and intracranial granulation tissue are 
investigated using immuno-light microscopic methods with markers for 
pencytes/vascular smooth muscle cells (VSMCs) (anti-a-smooth muscle (a-
sm) actin) and ECs (anti-von Willebrand factor, Ulex europaeus agglutinin 
type I) This study indicates a major contribution of a-sm actin positive 
pencytes/VSMCs to especially florid MVP in GBMs 
However, a-sm actin expression has also been described in ECs under 
certain culture conditions, and the possibility remains that the a-sm actin 
positive cells in the wall of newly formed microvessels as described in 
chapter 4 are in fact modified ECs that migrated to an abluminal position 
The study in chapter 5 further characterizes the nature of the cells 
contributing to MVP in GBMs by investigating at both the light- and 
electron microscopic level the distribution of a-sm actin, of a marker for 
ECs (EN4), and of a marker for "activated" pericytes (anti-High Molecular 
Weight-Melanoma Associated Antigen, anti-HMW-MAA) Additionally, in 
chapter 6 the distribution of aminopeptidase A as recognized by the 
monoclonal antibody RC38 is investigated by immuno-light and îmmuno-
electron microscopy in tissues showing neovascularization (tumors, 
granulation tissue) The presence of this ectoenzyme, that is involved in the 
metabolism of biologically active oligopeptides, on abluminal cells in the 
newly formed microvessels in GBMs and other tumors indicates an active 
role for pericytes in the angiogenic process 
The glomeruloid architecture of MVP in GBMs suggests a relative lack of 
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directional migration of proliferating microvascular cells into the 
surrounding glial (tumor) tissue 3435. Experimental data show that 
directional invasion of ECs is controlled by the ability of these cells to 
exert mechanical forces on the surrounding ECM 3638 Most of the 
identified endothelial adhesion molecules for ECM components are 
members of a family of aß-heterodimeric cell membrane receptors called 
integrins 3M1. In chapter 7 the expression of (subunits of) ECM-binding 
integrins (αΐ-аб, αν, ßl, ß3-ß5, avß3, avß5) and of complementary 
ECM-components (collagen I and IV, laminin, fibronectin, vitronectin) 
in/around florid MVP is compared with the expression in/around delicate 
microvessels in GBMs, normal brain, and intracerebral metastatic 
carcinomas. 
In chapter 8 the pathobiological and clinical aspects of angiogenesis in 
human brain tumors are reviewed. The aim of this review is to put the 
expectations about the value of anti-angiogenic therapy for human brain 
tumors into perspective of the anatomic realities of the vasculature and 
growth pattern of brain tumors. Since most studies on angiogenesis in brain 
tumors concentrated on astrocytic neoplasms, these tumors are highlighted 
in this review, but other tumors with perhaps more favorable tumor-
vasculature relationships are also discussed. 
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Chapter 2 
Summary 
Since histologically prominent microvascular proliferation (MVP) is 
frequently present in glioblastoma multiforme (GBM), it has been 
hypothesized that this neoplasm is particularly dependent on 
neovascularization for its continued growth, and that anti-angiogenic 
therapy might be especially useful In order to quantify the histological 
aspects of MVP in gliomas, we developed a method for computer-assisted 
image analysis of the specifically visualized microvasculature in glial 
tissue This method was used to compare several vascular parameters in 
histological whole tumor sections of untreated human GBMs with those in 
histologically normal cerebral cortex and white matter Compared to 
normal cerebral white matter, in GBMs a significant increase in mean 
number, area, and perimeter of blood vessels per microscopic field was 
present In a substantial number of tumor fields, however, the vascular 
density was in the range of that for normal cerebral white matter The 
striking heterogeneity of the microvasculature within GBMs was illustrated 
by the significantly higher standard deviation for the vascular parameters in 
tumor tissue. The results of the present study suggest that many regions of 
GBMs are not overtly angiogenesis dependent, and may be difficult to treat 
by anti-angiogenic therapy alone. The described method to quantify 
vascular parameters in histological sections of gliomas by computer-assisted 
image analysis appears to be feasible and reproducible 
18 
Quantification in glioblastomas 
Introduction 
Angiogenesis is considered a prerequisite for the continued growth of solid 
tumors Anti-angiogenic therapy might therefore lead to inhibition of tumor 
growth ' 3 Florid microvascular proliferation (MVP) is a remarkable and 
well-known histological feature of malignant gliomas 4 5 In 1972, a 
quantitative method for histologic grading of tumor angiogenesis, the 
"Microscopic Angiogenesis Grading System" (MAGS) was published 6 
The MAGS-score is based on three parameters vasoprohferation, 
endothelial cell hyperplasia, and endothelial cytology GBMs showing 
glomeruloid MVP appeared to be on the "endothelial-nch" end of the 
spectrum The high MAGS-score m GBMs led to the suggestion that these 
"endothelial-nch" tumors depend more on extensive neovascularization for 
their continued growth than "endothehal-poor" tumors 6 Anti-angiogenic 
drugs were therefore considered as a potential therapy for malignant 
gliomas 1 2 7 8 However, the MAGS-score is relatively liable to 
interobserver variation and does not account for the heterogeneity of the 
tumor tissue, since this score is assessed m an area of maximum vascular 
density Furthermore, the well vascularized appearance of malignant 
gliomas might be misleading, as the surrounding normal brain might be 
supplied with delicate blood vessels that are not so easily seen as the 
prominent tumor vessels 9 In the present study, a more objective method 
consisting of a quantitative analysis of the specifically visualized 
microvasculature in glial tissue is described Hereby, several vascular 
parameters in whole tumor sections of untreated human GBMs are 
compared with those in histologically normal cerebral cortex and white 
matter 
Materials and Methods 
Human brains of 7 adults with untreated cerebral GBMs were studied The 
brains were formalin-fixed and cut in 1 cm thick slices Of each brain one 
representative coronal or horizontal slice with tumor was embedded in 
paraffin With a sliding microtome, 12 μ "whole tumor sections" were cut 
containing the whole tumor and a variable, but mostly ample amount of 
19 
Chapter 2 
histologically normal, cerebral cortex and white matter. In order to 
highlight the vascular basement membranes these sections were stained 
immunohistochemically with a prediluted mouse monoclonal anti-collagen 
IV antibody (Biomeda Corporation, Foster City, Calif., USA) and counter-
stained with the Periodic Acid Schiff (PAS) and hematoxylin staining. 
Immunochemistry for collagen IV was performed using the Autoprobe III 
(Strep-Avidin-Biotin) Universal Detection System (Biomeda), while 3,3'-
Diaminobenzidine tetrahydrochloride (DAB) (Sigma Diagnostics, St. Louis, 
MO, USA) was used as a chromogen. The tumor was microscopically 
delineated by a neuropathologist (PW) and large necrotic foci were 
indicated and excluded from further analysis. Then a transparant grid with 
squares of 1 mm2 was fixed to the slide and in each slide squares were 
selected in the following four categories: 
A. "random tumor": without knowledge of the architecture of the tumor 
up to 35 squares were chosen in the delineated tumor area at a regular 
distance from each other; squares in which during subsequent 
microscopical analysis more than 1/4 appeared to be occupied by 
necrotic tissue were later on discarded; in each case at least 28 squares 
of random tumor were available for quantitative analysis. 
B. "pre-selected tumor": after microscopical evaluation of the slides in the 
delineated tumor area 12 squares were selected in which glomeruloid 
MVP and/or a relatively high number of blood vessels was present. 
C. "normal cerebral white matter": after microscopical evaluation of the 
slides 12 squares were randomly selected in histologically normal 
cerebral white matter. 
D. "normal cerebral cortex": after microscopical evaluation of the slides 
12 squares were randomly selected in histologically normal cerebral 
cortex. 
Normal cerebral cortex and white matter were generally selected in areas 
remote from the tumor tissue, in 3 of the 7 whole tumor sections (case 4, 
5, and 6) normal brain tissue of the contralateral hemisphere was available 
and used for assessment of the parameters. 
For image acquisition a Kontron Vidasplus image analysis system (Kontron 
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GmbH, Eching, Germany) was attached to a Sony RGB CCD camera, 
mounted on top of a Zeiss light microscope In every selected square one 
microscopic field was digitized at lOOx magnification and shown on an 
image monitor One by one these images, measuring 0 17 mm2 each, were 
analyzed First, a threshold level was set by the observer in the normalized 
grey level to distinguish vascular profiles from the surrounding tissue, 
resulting in a binary image Morphological operations were used to remove 
noise and to fill the lumina of the vascular profiles The entire enclosed 
area of these profiles was used for the calculation of the vascular 
parameters On the basis of comparison of the original and the binary 
image, when necessary correction of the binary image could be performed 
by erasing non-vascular structures and completing vascular profiles using a 
mouse After acceptation of this binary image, a second threshold value 
was set to discriminate the nuclei in the tissue outside the vascular profiles 
All calculated data were collected in a database for further statistical 
evaluation 
In each selected field, four vascular parameters (vessel number, vessel 
area, vessel perimeter, and vessel diameter), a parameter for the cellulanty 
of the extravascular tissue (tissue cellulanty), and one combined parameter 
(relative vessel perimeter) were assessed by one observer (JAWMvdL) 
These quantitative histological parameters are defined in table 1 
In every case, the mean value (mean), the median value (median), and the 
standard deviation of the six parameters was assessed in all four tissue 
categories (Α-D) Since the study was meant to compare tumor tissue 
(random and pre-selected) with normal cerebral cortex and white matter, 
the differences between the tissue types for the mean, median, and standard 
deviation of the parameters were statistically evaluated with a Wilcoxon 
matched paired, signed rank test, normal a = 0 05, with Bonferroni-
correction actual a = 0 017 In order to evaluate the reproducabihty of 
this computerized, quantitative analysis, the scores of two independent 
observers (PW, JAWMvdL) for all parameters in 84 exactly the same 
images of pre-selected tumor (B) and of normal cerebral white matter (C) 
were compared 
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TABLE 1. DEFINITIONS OF QUANTITATIVE HISTOLOGICAL PARAMETERS 
vessel number - number of complete vascular profiles in a field, each vascular profile 
demarcated from the surrounding tissue by a continuous basement membrane was 
considered as a separate blood vessel; a glomeruloid blood vessel with multiple lumina 
and surrounded by a continuous basement membrane was thus considered as one 
vascular profile; vessel number is the vascular density of the field. 
vessel area - sum of areas of all individual vascular profiles in a field in μ2. 
vessel perimeter - sum of perimeters of all individual vascular profiles in a field in μ, vessel 
perimeter indicates the microvascular surface potentially available for diffusion of 
oxygen and nutrients in a field 
vessel diameter - approximation of the mean diameter of all complete vascular profiles in a 
field, to assess this parameter, first the square of the shortest distance of each individual 
pixel in a vascular profile to the edge of this profile is determined (distance expressed 
in number of pixels); then the mean of this value for all pixels in that vascular profile is 
assessed, finally, these mean values for all complete vascular profiles in a field are 
averaged 
tissue cellulanty - number of nuclei outside the vascular profiles in a field, corrected for the 
area occupied by the vascular profiles in this field; tissue cellulanty is expressed per 
100 μ2 and indicates the cellulanty of the extravascular tissue in a field. 
relative vessel perimeter - ratio between vessel perimeter and number of nuclei in the 
extravascular tissue in a field; the relative vessel perimeter indicates the microvascular 
surface available for diffusion per cell in the extravascular tissue in a field 
Results 
Light microscopy 
The combined PAS-collagen IV staining procedure resulted in a brown 
staining of the basement membranes of the blood vessels and a blue-purple 
staining of the nuclei. Although most of the analyzed random tumor tissue 
fields were located in white matter, especially in case 2 and 7 up to 20% of 
these fields were located in the cerebral cortex. In the analyzed fields in 
tumor tissue and in normal cerebral cortex and white matter, no particular 
orientation of the microvessels was recognized and only sporadically were 
arteries and veins found. In the pre-selected tumor fields (category B), 
glomeruloid MVP was extensively present in case 2 and 6, locally present 
in case 4, sporadically present in case 1,3, and 5, and absent in case 7 
The estimated number of blood vessels in these pre-selected tumor fields 
was locally high in case 3, 5, and 7, and moderate in case 1, 2, 4, and 6. 
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Quantitative analysis 
The results of the quantitative analysis and the statistical evaluation of these 
results are shown in fig. 1 Examples of the scores for the six parameters 
in different fields are shown in fig. 2 Compared to normal cerebral white 
matter, in random tumor the standard deviation for the vascular parameters 
(vessel number, vessel area, vessel perimeter, vessel diameter) was 
significantly increased The mean and median for vessel area and vessel 
perimeter and the mean for vessel number were significantly higher in 
random tumor than in normal cerebral white matter In most cases, 
however, in more than 50% of the random tumor fields the score for vessel 
number was in the range of the scores for normal cerebral white matter In 
normal cerebral cortex the mean and median for vessel number, vessel 
area, and vessel perimeter were significantly higher, and the mean and 
median for vessel diameter were significantly lower, than in normal 
cerebral white matter 
The mean, median and standard deviation for tissue cellulanty were 
significantly higher in random and pre-selected tumor than in normal 
cerebral cortex and white matter, while in normal cerebral white matter the 
mean and median for this parameter were significantly higher than in 
normal cerebral cortex The mean and median for relative vessel perimeter 
in random and in pre-selected tumor were not significantly different from 
those in normal cerebral white matter and were significantly lower than 
those in normal cerebral cortex In the random tumor fields no significant 
correlation was found between tissue cellulanty and the four vascular 
parameters 
The pre-selected tumor fields of case 2 and 6 with extensive glomeruloid 
MVP showed a relatively high vessel area and vessel diameter and low 
vessel number compared to the preselected tumor fields of other cases On 
the other hand, a relatively high vessel number was found in the pre-
selected tumor fields of cases in which before quantitative analysis the 
number of blood vessels was estimated as locally high (case 3 ,5 , and 7) 
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FIG. 1. Quantification of the parameters a. vessel number, b. vessel area, с vessel 
perimeter, d. vessel diameter, e. tissue cellularity, f. relative vessel perimeter in random 
tumor tissue (A), pre-selected tumor tissue (B), normal cerebral white matter (C), and 
normal cerebral cortex (D) of case 1 to 7; in the box-plot the two ends of the rectangle 
represent the lower and upper quartile of the distribution, the median is shown by a line 
cutting the rectangle, and the lines extending from the ends of the rectangle indicate the 
smallest and largest value within 1.5 times the interquartile range; in the inset the statistical 
evaluation of results is shown; vs = versus; mn = mean value; md = median value; sd = 
standard deviation; > = significantly higher; < = significantly lower; ns = no significant 
difference; significant difference when ρ < 0.017; for further information about statistical 
evaluation and tissue categories, see Materials and Methods; for definitions of parameters, 
see table 1. 
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vessel number = 14 vessel number = 69 vessel number = 14 vessel number = 31 
vessel aree = 20656 vessel area = 19964 vessel area »3927 vessel area = 9426 
vessel perimeter = 2437 vessel perimeter = 5968 vessel perimeter = 1351 vessel perimeter = 3745 
vessel diameter = 8 . 7 4 vessel diameter = 1.25 vessel diameter = 1.19 vessel diameter = 0 . 9 2 6 
tissue cellularity = 0 . 5 5 3 tissue cel/ularity = 0 . 7 5 8 tissue cellularity =0 .175 tissue cellularity = 0 . 1 5 2 
rel. vessel perimeter = 2.99 rel. vessel perimeter = 5.30 rel. vessel perimeter = 4.71 rel. vessel perimeter = 15.5 
FIG. 2. Examples of computer-assisted image analysis of six histological parameters in 
microscopic fields of GBM and of normal cerebral white matter and cortex; a - d. digitized 
image on monitor (PAS-collagen IV staining, original magnification lOOx, image area 0.17 
mm2); e - h. delineation of microvascular profiles (grey structures) and identification of 
nuclei in extravascular tissue (black dots) after setting of appropriate thresholds; a, e. GBM 
with glomeruloid MVP; b, f. GBM with high vascular density; c, g. normal cerebral white 
matter; d, h. normal cerebral cortex; for definitions of parameters, see table 1; for further 
information about image analysis procedure and tissue categories, see Materials and 
Methods. 
The correlation-coefficient between the scores of the two independent 
observers was higher than 0.9 for all parameters in the 84 fields of pre-
selected tumor and of normal cerebral white matter. Between the scores of 
these observers, no relevant systematic or incidental differences were found 
for all parameters in normal cerebral white matter and for the parameters 
vessel area, vessel perimeter, tissue cellularity and relative vessel perimeter 
in pre-selected tumor. The highest systematic and incidental differences 
between the two independent observers occurred for the parameters vessel 
number and vessel diameter in pre-selected tumor, the systematic 
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differences for vessel number and vessel diameter being 16.5% and 11.3% 
respectively, and the incidental difference for both these parameters being 
18.4% (p < 0.001). However, even these differences had little impact on 
the final scores for the mean, median and standard deviation of vessel 
number and vessel diameter in pre-selected tumor. 
Discussion 
Quantitative histological studies on the microvasculature in gliomas 
Few quantitative histological studies on the microvasculature in gliomas 
have been performed. A morphometric study of the microvasculature in 
and around rat gliomas showed no significant rise in vascular density 
around the tumor and a drop of vascular density towards the center of the 
tumor l0. In semithin sections of human GBMs a significant decrease in 
vascular density was found in and around the tumor compared to normal 
white matter, while the vascular volume was increased in the tumor but 
decreased around the tumor ". In a biopsy study of human cortex 
infiltrated by malignant glioma, an increase in vascular density only 
occurred in some cases of markedly and completely infiltrated cortex. This 
angiogenic reaction to tumor infiltration was considered as late, slow and 
inconstant I2. In another study, a decrease in intercapillary distance was 
described in the proliferating area of human gliomas 13. The heterogeneity 
of the microvasculature in GBMs has been illustrated by a morphometric 
study with a graphical tablet on microscopical photographs of these tumors 
'
4
. Recently, automated image analysis was introduced as a tool for a more 
objective histological assessment of angiogenesis in tumors l5"17. In the 
present study, we describe a method for computer-assisted image analysis 
of the specifically visualized microvasculature in glial tissue. We applied 
this method on whole tumor sections of GBMs which had not been treated 
so that the microvascular status was not influenced by irradiation and/or 
chemotherapy. Furthermore, histologically normal cerebral cortex and 
white matter were present in all whole tumor sections and could be used as 
internal controls. 
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Methodological considerations 
The accentuation of the objects of interest is of paramount importance for 
computer-assisted image analysis. Since in normal brain tissue and in glial 
neoplasms collagen IV is essentially confined to the wall of blood vessels 
'
82
°, the microvasculature in the whole tumor sections was generally easy 
to identify in the combined PAS-collagen IV staining. In the present study 
a blood vessel was defined on the basis of a demarcation of the 
microvascular profile from the surrounding tissue by a continuous 
basement membrane, visualized in the PAS-collagen IV staining. In other 
studies, the number of vessel lumina in a field was determined as an 
indication for the vascularity of the tissue, and an immunohistochemical 
staining for endothelial cells was sometimes used to highlight these vessel 
lumina 614. In GBMs the number of microvascular lumina will generally be 
higher than the number of microvascular profiles as defined in this study, 
because some of these profiles contain multiple lumina. 
In the present study the genesis of new microvessels in tumor tissue will be 
underestimated when a simultaneous expansion of the tumor tissue in 
between the blood vessels occurs, e.g. by accumulation of tumor cells or 
by edema. On the other hand, since the vascular density in normal cerebral 
cortex is higher than in normal cerebral white matter, a relatively high 
number of préexistent blood vessels can be expected in tumor tissue 
infiltrating in cerebral grey matter. An increased vascular density without 
the occurence of neovascularization might also be the result of collapse of 
the tumor tissue in between the blood vessels, e.g. by (partial) necrosis. 
Florid MVP in GBMs is described to be often present around necrotic foci 
and in borderzone areas where neoplastic cells invade the adjacent brain 
4,5 2
'. Since unequivocal delineation of a tumor border zone can be difficult 
in glial neoplasms because of a diffuse infiltrative growth pattern, in the 
present study the quantitative analysis was only performed in clear-cut 
tumor tissue and in normal cerebral cortex and white matter. The design of 
the present study is thus not suitable to analyze the topographical 
distribution of MVP in GBMs or to detect a relationship between MVP and 
necrosis in these tumors. 
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Unequivocal automated assessment of the diameter of branching vessels is 
difficult. Unlike vessel area and vessel perimeter, the parameter vessel 
diameter as defined in the present study is practically not influenced by 
branching of vessels or by the way the vessels are cut. 
Interpretation of the present findings 
The results of the present study illustrate the striking heterogeneity of 
GBMs for all vascular parameters. Compared to normal cerebral white 
matter, in random tumor the standard deviation for vessel number, vessel 
area, vessel perimeter, and vessel diameter, and the mean for vessel area, 
vessel perimeter and vessel number were significantly increased. On the 
other hand, in more than 50% of the random tumor fields the vessel 
number was in the range of the vessel number for normal cerebral white 
matter, suggesting that few new vessels had formed in such areas. 
The results for vessel number and vessel diameter in the normal cerebral 
cortex illustrate the high number of delicate blood vessels in this tissue. 
The relatively high standard deviation for vessel number in the normal 
cerebral cortex might be explained by the variation of vascular density 
across the depth of the cortex '°. Although the mean and median for vessel 
perimeter in random tumor are significantly higher than in normal cerebral 
white matter, because of the relatively high cellularity of random tumor 
tissue no significant difference is found for relative vessel perimeter 
between these tissues. 
In every case 12 fields of tumor tissue were selected on the basis of the 
"vascularity" of the tissue. Since the criterion used for selection was not 
unequivocal (presence of glomeruloid MVP and/or a relatively high 
number of blood vessels), a heterogeneous population of tumor fields was 
analyzed in this category of pre-selected tumor. The results of the analysis 
of these pre-selected tumor fields do however demonstrate the major effects 
of selection of fields on the basis of certain criteria before further 
quantitative analysis. The vessel diameter and vessel area were relatively 
high in pre-selected tumor fields with extensive glomeruloid MVP, while 
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the vessel number was relatively high in fields with an estimated high 
number of blood vessels This phenomenon also illustrates that the 
"vascularity of tissue" is a broad concept, not only determined by the 
vascular density, but also by other vascular parameters, like vessel area, 
vessel perimeter and vessel diameter As stated before, the presence of 
prominent blood vessels in glial tumors may give the impression of a 
highly vascularized tumor but does not necessarily mean that the vascular 
density is increased '4 
The reproducability of the described computerized method for quantitative 
analysis of the microvasculature was good The only relevant differences 
between the two independent observers were found for vessel number and 
vessel diameter in pre-selected tumor fields The very complicated 
microvascular pattern in some of these fields combined with a less crisp 
demarcation of some vascular profiles probably contributed to these 
differences In most cases, however, the interobserver differences had little 
influence on the mean, median and standard deviation of the parameters 
Pathobwlogical significance of MVP in gliomas 
More than 50 years ago it was described that astrocytic neoplasms 
generally show a diffuse, infiltrating in stead of a solid growth pattern, the 
growth of the tumor cells being guided by préexistent fiber tracts 2223 It 
has been suggested that these tumors can spread using existing vessels 
rather than being supplied by new ones 1012 The extent to which astrocytic 
neoplasms in general are angiogenesis-dependent therefore remains to be 
established 
Theoretically, when in astrocytic neoplasms the amount of tumor cells in a 
certain volume surpasses a critical number and a more solid growth pattern 
occurs or when tumor cells in a certain area become metabohcally hyper-
active (e g in more malignant neoplasms), the tumor tissue may outstrip 
préexistent blood vessels and become dependent on angiogenesis This 
process will be accompanied by local hypoxia, which is supposed to be an 
important factor in the development of MVP in gliomas 24"26 However, it 
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has been described that glomeruloid MVP in GBMs is usually not 
accompanied by any regional increase in density of tumor cells 5. 
Interestingly, in the present study also no significant correlation was found 
between the cellularity of the tumor tissue (tissue cellularity) and the four 
vascular parameters {vessel number, vessel area, vessel perimeter, vessel 
diameter). 
Florid MVP is a well-known feature of malignant gliomas, especially of 
GBMs 4·5 and might be the result of production of angiogenic factors in 
tumor cells of glial neoplasms 25"38, combined with a lack of directional 
microvascular growth in the tumor tissue 10·39. In florid MVP in gliomas in 
situ accumulation of both endothelial cells and vascular smooth muscle 
cells or pericytes has been described 40 ·41 . Since the contribution of these 
aberrant blood vessels to the viability of the tumor tissue is unclear l0, even 
in areas of malignant gliomas with prominent MVP the efficiency of anti-
angiogenic therapy remains to be seen. 
Conclusions 
A feasible and reproducable computer-assisted image analysis method is 
described to quantify multiple parameters of the microvasculature in 
histological sections of normal and neoplastic glial tissue. Application of 
this method on whole tumor sections of untreated human GBMs illustrates 
the striking heterogeneity of the microvasculature in these tumors such that 
the number of vessels in many tumor-containing areas does not exceed that 
of normal white matter. The significance of these findings in regard to the 
efficacy of anti-angiogenic therapy remains to be defined. The results do 
suggest, however, that many intratumoral regions may not be overtly 
angiogenesis-dependent and amenable to anti-angiogenic therapy. 
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Summary 
Since glioblastoma multiforme (GBM) frequently shows striking, 
glomeruloid microvascular proliferation (MVP), this tumor has become a 
strong candidate for anti-angiogenic therapy. However, the efficacy of anti-
angiogenic treatment may rather be determined by the extent of classic 
angiogenesis with the formation of delicate microvascular sprouts. 
Therefore, this study differentially quantifies the microvascular changes in 
supratentorial diffuse astrocytic neoplasms by computerized image analysis 
of histological sections in which the microvessels were highlighted by a 
combined anti-collagen IV/MIB-1 staining. Four microvascular parameters 
(number, area, perimeter, diameter), the cellularity of the glial tissue, and 
the MIB-1 labelling index were assessed in biopsies of astrocytoma (A, 
n=13), anaplastic astrocytoma (AA, n=14), and GBM (n = 20), and in 
normal cerebral cortex (n = 7) and white matter (n = 7). In As and AAs the 
microvascular parameters were not significantly different from each other, 
and the microvascular changes were generally limited compared to WM 
and CX. In contrast, the microvascular parameters in GBMs were highly 
variable, their mean value was significantly higher than in As and AAs. 
Our study shows that not only glomeruloid MVP, but also classic 
angiogenesis occurs mainly and only locally in GBMs. This finding implies 
that anti-angiogenic therapy will have limited effect on As and AAs, while 
the efficacy for GBM awaits further evaluation. 
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Introduction 
Solid tumors need to induce angiogenesis to meet the metabolic demands of 
a growing population of tumor cells 12 In tumor biopsies, the angiogenic 
capacity is reflected by the number of microvascular profiles in the area 
with the highest vessel number ("angiogenic hot spot"). In several tumor 
types (e g breast, prostate, and non-small cell lung carcinoma) an 
increased intratumoral microvessel density correlated directly with 
metastasis and/or inversely with survival 1 Given this critical role for 
vessels in the enlargement, and possibly metastatic potential, of solid 
tumors, the angiogenic process is a logical target for new anti-cancer 
therapies In fact, some anti-angiogenic agents are now being studied in 
phase 1 and 2 clinical trials for solid tumors like breast, colon, lung, and 
prostate cancer 4 
On the basis of four histopathological criteria (nuclear atypia, mitotic 
activity, microvascular proliferation (MVP), and necrosis) diffuse 
astrocytic neoplasms can be divided into three groups of increasing 
malignancy astrocytoma (A), anaplastic astrocytoma (AA), and 
glioblastoma multiforme (GBM) 56 GBM, the most frequent and most 
malignant human glial neoplasm, frequently shows glomeruloid MVP with 
multilayered proliferation of swollen endothelial cells and pericytes in the 
vessel wall 5 7 9 Because of this florid MVP, GBM has become a strong 
candidate for anti-angiogenic treatment 10 n Expectations for success were 
strengthened by animal studies in which the growth of glioma xenografts 
could indeed be inhibited by anti-angiogenic therapy M '7. 
Glomeruloid MVP in GBMs is attributed to the increased production and 
release of angiogenic factors, especially of Vascular Endothelial Growth 
Factor / Vascular Permeability Factor (VEGF/VPF) 1819 The VEGF 
expression appears to be upregulated by hypoxia 20 The functional 
significance of the aberrant, glomeruloid angiogenic reaction in GBMs is, 
however, unclear The glomeruloid architecture suggest that this angiogenic 
reaction is based on proliferation of microvascular cells, combined with a 
relative lack of directional migration of these cells into the surrounding 
glial tumor tissue 2122 The coexistence of glomeruloid MVP and 
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(sometimes extensive) necrosis in GBMs indicates that this angiogenic 
reaction occurred as a late, secondary effect of production of angiogenic 
factors by hypoxic tumor tissue, and that this reaction was insufficient or 
too late to save (part of) the endangered tumor tissue from death 2 3 2 4 . 
The efficacy of anti-angiogenic therapy for GBMs may rather be 
determined by the degree of classic angiogenesis with the formation of 
delicate microvascular sprouts. The extent of such classic angiogenesis in 
diffuse astrocytic tumors is not well established. The present study 
separately quantifies the different microvascular changes in diffuse 
astrocytic neoplasms with increasing grade of malignancy by computer 
assisted image analysis. 
Materials and Methods 
Tissues and staining 
For this study we selected formalin-fixed, paraffin embedded biopsy 
specimens of 47 supratentorial diffuse astrocytic neoplasms, as well as 
autopsy material from normal cerebral (frontal) cortex (CX, η=7) and 
subcortical white matter (WM, η = 7) of patients who had died of non-
cerebral disorders. After review of the histology in hematoxylin & eosin 
(H&E) stained sections according to the revised WHO-classification 6, the 
tumors were divided in three categories: astrocytoma (A, n=13), anaplastic 
astrocytoma (AA, n=14), and GBM (n = 20). Next, 4 μπι serial sections 
were cut of representative blocks and stained with H&E and with a 
combined immunohistochemical collagen IV (col.IV) and MIB-1 staining. 
For the latter staining, the histological sections were first pretreated in a 
magnetron, then the monoclonal antibody for MIB-1 (Immunotech/Coulter, 
Mijdrecht, The Netherlands) was applied in a two step procedure, followed 
by pronase pretreatment and detection of col.IV by a monoclonal antibody 
(Sigma, St. Louis, MO, USA) in a three step procedure. In the 
col.IV/MIB-1 staining, col.IV was marked with a red chromogen (Vector 
Red, Vector Laboratories, Inc., Burlingame, CA, USA), MIB-1 positive 
nuclei with a brown chromogen (3,3'-Diaminobenzidine tetrahydrochloride 
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(DAB), Sigma), and MIB-1 negative nuclei were stained blue with the 
hematoxylin counterstaining. Since in astrocytic tumors col.IV is essentially 
confined to the vessel wall ц , in these tumors the microvascular profiles 
are highlighted by the col.IV staining. The MIB-1 antibody has been shown 
to be a useful marker for the assessment of the proliferative activity in 
paraffin-embedded glioma tissue 2 6 2 8 . 
Computerized analysis 
Computerized quantitative analysis was performed essentially as previously 
described 2 \ application of this method by two independent observers in 84 
exactly the same fields did not reveal relevant systematic or incidental 
differences between the scores of these observers. Briefly, for image 
analysis we used the Kontron Vidasplus system (Kontron GmbH, Eching, 
Germany). After evaluation of the histology in the H&E stained slides, in 
every col.IV/MIB-1 stained slide 10-15 random microscopic fields were 
digitized at lOOx magnification. A field was discarded when more than 
25% was occupied by necrotic tissue. All the images (measuring 0.17 mm2 
each) were analyzed by one investigator (PW). The vascular profiles were 
distinguished from the surrounding tissue by true color segmentation. 
Several tools were available for correction of the initial segmented image 
on the basis of comparison of the original and the segmented image. The 
entire enclosed area of the vascular profiles was used for the calculation of 
the vascular parameters. After segmentation of the vascular profiles, 
intensity threshold values were set to discriminate the MIB-1 positive and 
MIB-1 negative nuclei in the tissue outside the vascular profiles. 
Assessment of parameters 
In each selected field, four microvascular parameters (vessel number, vessel 
area, vessel perimeter, vessel diameter) and two other parameters (tissue 
cellularity, MIB-1 labelling index (MIB-1 LI)) were assessed, most of these 
parameters were defined as previously described 29. In short, vessel number 
is the number of separate vascular profiles in a microscopic field 
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(expressed per mm2), vessel area is the sum of areas of all vascular 
profiles in a field (expressed as percentage of field area), vessel perimeter 
is the sum of perimeters of all vascular profiles in a field (expressed as 
μπι/mm2), and tissue cellulanty is the number of nuclei outside the vascular 
profiles in a field corrected for the area occupied by the vascular profiles 
in that field (expressed per mm2) In the present study, the diameter of a 
vascular profile was assessed by using the medial axis of the profile For 
every pixel of this axis, the distance to the object contour was calculated, 
and the largest distance perpendicular to the axis was multiplied by two and 
used as a measure for the diameter of that vascular profile The vessel 
diameter of a field was defined as the mean value of the diameters of all 
complete vascular profiles in that field and expressed in μίτι The MIB-1 
LI was defined as the percentage of MIB-1 positive nuclei in the 
extravascular tissue in a field Additionally, in analogy with the method 
described by Weidner 3, in the col IV/MIB-1 stained slide of each case the 
area with the highest density of distinct col IV positive vascular profiles 
was determined at low power (x25) In this "angiogenic hot spot" the 
number of profiles was counted in a x250 field (x25 objective and xlO 
ocular, 0 71 mm2 per field) by one neuropathologist (PW) All digitized 
images were numbered and stored to allow optimal retrospective 
interpretation of the quantitative analysis 
Statistical evaluation 
All calculated data were collected m a database for further statistical 
evaluation With a statistical software package (SPSS for Windows, SPSS 
Ine , Chicago, IL, USA) Student t-tests were performed to determine the 
level of significance of the differences between the histological parameters 
in the five tissue categories (CX, WM, A, AA, or GBM) The mean value 
(MN) and standard deviation (SD) of these parameters in a tissue category 
were computed by assessment of the MN and SD per case and than per 
tissue category In all cases, the correlation was assessed between vessel 
number and vessel diameter, vessel number and tissue cellulanty, vessel 
diameter and tissue cellulanty, vessel number and MIB-1 LI, and vessel 
diameter and MIB-1 LI The SPSS package was also used to compute the 
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Pearson correlation coefficients between the parameters within a case and 
to determine the level of statistical significance of the correlation. 
Results 
Examples of the computer-assisted quantification of histological parameters 
in microscopic fields of WM, AA, and GBM are shown in fig. 1. The 
results of the quantitative analysis are summarized in fig. 2 and 3. 
Glomeruloid MVP was (locally) present in 13 out of 20 GBMs. In the 
col.IV staining a glomeruloid microvessel containing multiple lumina was 
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F I G . 1. Examples of computer-assisted quantification of 6 histological parameters in 
microscopic fields of normal cerebral white matter (WM) (a,e), anaplastic astrocytoma 
(AA) (b,f), and glioblastoma multiforme (GBM) (c,d,g,h); a - d digitized image (collagen 
І /МШ-l staining, original magnification lOOx, image area 0.17 mm2); e - h delineation of 
microvascular profiles (dark grey) and identification of МШ-1 positive (black) and МШ-1 
negative nuclei (light grey) in extravascular tissue after segmentation of image; note the low 
vessel number in AA (b,f), the high number of delicate microvessels in one field (c,g) and 
the few but glomeruloid microvessels in another field of GBM (d,h); for further informati­
on about image analysis procedure and definitions of parameters, see Materials and 
Methods. 
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FiG. 2 Quantification of the microvascular parameters vessel number (a), vessel area (b), 
vessel perimeter (c), and vessel diameter (d) in normal cerebral cortex (CX), normal 
cerebral white matter (WM), astrocytoma (A), anaplastic astrocytoma (AA), and 
glioblastoma multiforme (GBM), in the box-plot the two ends of the rectangle represent the 
lower and upper quartile of the distribution, the median is shown by a line cutting the 
rectangle, and the ends of the lines extending from the rectangle indicate the smallest and 
largest value, in the inset the statistical evaluation of the results is shown, MN = mean 
value, SD = standard deviation, > = significantly higher, < = significantly lower, ns = 
no significant difference, significant difference when ρ < 0 05, for further information 
about statistical evaluation, see Materials and Methods 
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delineated as one microvascular profile with a relatively large diameter. In 
most fields of the astrocytic tumors the nature of the préexistent brain 
tissue (white matter, cortex, subcortical grey matter) could not 
unequivocally be identified. In 27 tumors (9 GBMs, 12 AAs, 6 As) some 
fields contained isolated neurons in between the tumor cells, implicating 
that these tumors were at least partly localized in cerebral grey matter. 
Vessel number and microvessel count in "angiogenic hot spot " (fig. 2a,3) 
Most fields in As, AAs, and GBMs showed a vessel number in the range of 
WM or CX, while in some fields the vessel number was lower than in 
WM. Review of the stored images revealed that fields in As and AAs with 
a relatively low vessel number often showed a loose texture of the 
intervascular tumor tissue (fig. lb). In GBMs a relatively low vessel 
number also occurred in fields with glomeruloid MVP (fig. Id). In 
retrospect, 6 of 10 As and AAs with a maximum vessel number above the 
range of WM locally contained some neurons. Only in some GBMs fields 
were encountered with a vessel number well above that in CX, in those 
fields the vessels were delicate (fig. lc). Like vessel number, the 
microvessel count in the "angiogenic hot spot" was in some As, AAs, and 
GBMs in range of or lower than in WM, in other tumors in range of CX, 
and only in some GBMs higher than in CX (fig. 3). 
FIG. 3. Microvessel count in 
"angiogenic hot spot" of normal 
cerebral cortex (CX), normal 
cerebral white matter (WM), 
astrocytoma (A), anaplastic astro-
cytoma (AA), and glioblastoma 
multiforme (GBM). Each circle 
represents a case. Note that this 
parameter, that was assessed in 
analogy with the method advoca-
ted by Weidner 3, shows a similar 
distribution over the five tissue 
categories as the upper range of 
the vessel number (fig. 2a). 
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Vessel area and vessel perimeter (fig. 2b,c) 
In most fields of As and AAs the vessel area and vessel perimeter were in 
the range of those for WM or CX. In many fields of GBMs and some 
fields of As and AAs these parameters were higher than in CX. Review of 
these fields showed that a markedly increased vessel area was associated 
with microvascular dilation (A, A A) and/or glomeruloid MVP (GBM) (fig. 
ld,h). A relatively high vessel perimeter could be the result of both the 
formation of delicate microvascular sprouts and of florid MVP (fig. 
lc,d,g,h). In some fields of especially As and AAs the vessel area and 
vessel perimeter were lower than in WM, such fields contained few and 
relatively delicate microvessels (fig. lb,f). 
Vessel diameter (fig. 2d) 
In most fields of As and AAs, the vessel diameter was in the range of 
WM. Few fields in As and AAs, and many fields in GBMs showed an 
increased vessel diameter compared to WM. Review of the stored images 
revealed that in GBMs the latter areas generally harboured florid MVP 
(fig. ld,h), while in As and AAs the increased vessel diameter could be 
explained by dilatation of the microvessels and/or the presence of venules 
in a field with few capillaries. 
Correlation of microvascular and other parameters 
Within 21 of the 47 astrocytic neoplasms (6 As, 5 AAs, and 10 GBMs) a 
significant negative correlation was found between vessel number and 
vessel diameter. In As and AAs, this phenomenon was determined by the 
presence of fields with relatively many but delicate microvessels, while 
GBMs additionally showed fields with few but glomeruloid microvessels on 
the other end of the spectrum (see fig. 4 for example). The tissue 
cellularity within the astrocytic tumors did not significantly correlate with 
vessel number or vessel diameter. The MIB-1 LI ranged in As from 0% to 
5% per field, in AAs and GBMs from less than 1% to 60% per field, and 
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was 0% in CX and WM. No consistent correlation was found between the 
MIB-1 LI and vessel number or between the MIB-1 LI and vessel diameter 
within the tumors. 
F I G . 4. Example of a case of 
glioblastoma multiforme (GBM) 
showing an inverse correlation 
between vessel number and vessel 
diameter (correlation coefficient 
= -0.67, ρ = 0 006) Each trian­
gle represents an analyzed field in 
this GBM. Note that this correla­
tion is determined by the presence 
of multiple fields with a high 
number of delicate microvessels, 
and, on the other hand, some 
fields showing only few vessels 
with a relatively large diameter 
(consistent with glomeruloid 
microvascular proliferation). 
Discussion 
Interpretation of results 
Tumor microvessels may originate from two different populations: a) 
préexistent vessels incorporated into the tumor tissue and b) microvessels 
arising from neovascularization 30. The astrocytic tumors investigated in 
this study are well recognized for their diffuse infiltrative growth along 
white matter tracts and blood vessels 7 · 3 1 3 3 . Consequently, in these tumors 
many vessels may be incorporated, préexistent vessels. 
Our study shows that the infiltration of As and AAs in brain tissue is 
accompanied by limited microvascular changes. Locally, some delicate 
microvascular sprouts may be formed, but infiltration in the abundantly 
vascularized cerebral grey matter may also account for a relatively high 
vessel number Compared to As and AAs, in GBMs the MN and SD of all 
microvascular parameters are significantly increased. The local, marked 
increase in vessel diameter in GBMs (but not in As and AAs) is a 
reflection of the presence of glomeruloid MVP that was used to distinguish 
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these tumors from the less malignant diffuse astrocytic neoplasms. In other 
areas of GBMs classic angiogenesis with directional growth of 
microvascular sprouts did occur, resulting in a very high vessel number. 
The factors responsible for the local formation of glomeruloid instead of 
delicate microvessels in GBMs remain to be elucidated. 
There is clear evidence that two distinct genetic pathways lead to the 
formation of GBMs. One pathway starts with As and results via AAs in 
(secondary) GBMs, another pathway leads directly to the development of 
("de novo") GBMs 34. Since information about the genetic changes of the 
tumors in our series was not available, we were unable to investigate 
differences in angiogenic profiles between these two types of GBMs. 
About half of the astrocytic tumors showed a significant inverse correlation 
between vessel number and vessel diameter. This finding can be explained 
by (a combination of) three factors: infiltrative growth in cerebral grey 
matter with a relatively high number of delicate microvessels, the 
formation of new and delicate microvascular sprouts, and the presence of 
glomeruloid MVP with relatively few but large microvessels in a 
microscopic field. No consistent correlation was found between tissue 
cellularity or MIB-1 LI and the microvascular parameters within the 
astrocytic neoplasms. 
Comparison with other quantitative studies 
The results of the present quantification of microvascular parameters in 
CX, WM, and biopsy material of GBMs are very similar to those of our 
previous study on post-mortem whole-tumor sections of GBMs M, 
indicating that in this context the described quantitative method is 
reproducible. Only two other studies quantified not only the number, but 
also the diameter of microvessels in human gliomas. One study, 
performing morphometric analysis with a graphical tablet on microscopical 
photographs, also demonstrated the impressive heterogeneity of the 
microvasculature in GBMs 35. Unlike this study, we did not find significant 
microvascular differences between As and AAs. This may be explained by 
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the criteria that were used to distinguish As from AAs. In our study the 
revised WHO-classification was applied 6, according to this classification 
florid MVP and necrosis are absent in both As and AAs, while an 
important (and often the only) histological difference between As and AAs 
is the presence of mitotic activity in the latter. A biopsy study of human 
cortex infiltrated by malignant glioma reported on an increase in diameter 
and number of vessels 36. The increased number of vessels was described 
as a late, slow and inconstant phenomenon, while an increased diameter 
was mainly attributed to proliferation of microvascular cells in the vessel 
wall. 
A study of a wide histological variety of brain tumors in children 
(including five As and one GBM) reported on a correlation between the 
concentration of the angiogenic peptide basic fibroblast growth factor in the 
cerebrospinal fluid and the microvessel count in the "angiogenic hot spot" 
37
. More recently, Leon et al. assessed not only the microvessel count, but 
also graded the microvessel density (from 1+ to 4 + ) in supratentorial 
astrocytic tumors in adults 38. Tumors with glomeruloid MVP were graded 
as 3+ or higher. In this study, more than 90% of the tumors were AAs 
and GBMs. Since some of these AAs were described to contain 
glomeruloid blood vessels, these tumors would probably be designated as 
GBMs according to the revised WHO-classification6'39. 
Prognostic and therapeutic consequences 
For "routine" histopathological examination, the presence of glomeruloid 
MVP in the context of a mitotically active, diffuse astrocytic neoplasm 
with nuclear polymorphism is a useful phenomenon to distinguish GBMs 
from AAs 6'39. Assessment of the microvessel count in the "angiogenic hot 
spot" has become a new prognostic indicator in various cancerous lesions 3. 
In one study of breast carcinomas the vessel area also offered prognostic 
information "°. The above mentioned study of Leon et al. 38 reported that 
both microvessel count and microvessel grade correlated significantly with 
survival in supratentorial astrocytic brain tumors in adults. 
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Some fundamental differences exist between the microvessel count in the 
"angiogenic hot spot" and the vessel number. The first parameter is 
assessed by counting the number of microvessels in a x250 microscopic 
field of 0.71 mm2 in the area with the highest density of distinct vascular 
profiles. The vessel number is determined in 10-15 random microscopic 
fields, each measuring 0.17 mm2. The microvessel count in the "angiogenic 
hot spot" represents an estimation of the maximum angiogenic capacity of a 
tumor, the vessel number reflects (part of) the microvascular heterogeneity 
of a tumor. We are presently investigating the additional prognostic 
information of the vessel number, vessel area, vessel diameter, and of the 
microvessel count in the "angiogenic hot spot" in our group of patients. 
The efficacy of anti-angiogenic tumor therapy will be determined by the 
amount of tumor tissue that is dependent on neovascularization for 
sustained growth and the level of functional neovascularization in these 
areas. Diffusely infiltrating astrocytic tumors may grow using existing ves-
sels rather than being supplied by new ones, particularly in the critical 
peripheral infiltrative margins 22,36. Our study shows that the angiogenic 
reactions in As and AAs are limited, thereby providing evidence that these 
tumors are not good candidates for anti-angiogenic treatment. 
The presence of glomeruloid MVP in GBMs gives the impression of a 
highly vascularized tumor. However, the morphological appearance of the 
tumor vasculature does not allow direct judgments concerning the tumor 
blood flow 30 ·41 . The aberrant architecture of glomeruloid MVP and its 
paradoxical coexistence with (sometimes extensive) foci of necrosis suggest 
that its contribution to the viability of the tumor tissue may be limited 23·24. 
Even a high number of delicate tumor vessels in GBMs does not guarantee 
a high nutritive flow. In human gliomas xenografted in nude mice the 
perfused fraction of tumor vessels ranged from 20% to 85% 42. The extent 
to which GBMs are angiogenesis-dependent therefore remains to be 
established. 
The success of anti-angiogenic therapy for glioma xenografts in animal 
models should be interpreted with caution. While some studies describe 
extensive migration of human glioma cells xenografted in the brain of 
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laboratory animals 4344, these glioma models are generally expansive rather 
than diffusely infiltrative 5^ and, according to the hypothesis of Folkman '2 , 
a more solid growth pattern of glioma models implicates an increased 
dependency on angiogenesis. 
Concluding remarks 
For accurate assessment of the extent of angiogenesis in infiltrative brain 
tumors, the variation in vascularity of normal brain tissue has to be taken 
into consideration. Our study quantifies several aspects of the 
microvascular changes in diffuse astrocytic neoplasms with increasing 
grade of malignancy. Since the microvascular changes in As and AAs are 
limited compared to WM and CX, these tumors don't seem to be good 
candidates for anti-angiogenic treatment. GBMs, on the other hand, locally 
show marked microvascular changes, ranging from the formation of many 
delicate microvessels to glomeruloid MVP. For routine histopathological 
examination, the latter angiogenic reaction is a helpful phenomenon to 
diagnose high-grade malignancy in diffuse astrocytic tumors The 
additional prognostic significance of other microvascular parameters needs 
further evaluation. The functional significance of both the formation of 
glomeruloid and of delicate microvessels (and thus the efficacy of 
abrogation of these angiogenic reactions) in GBMs remains to be 
established. 
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Summary 
Since the origin of cells contributing to microvascular proliferation (MVP) 
in glial neoplasms is unsettled, a light microscopic and immuno-
histochemical study for vascular smooth muscle cells and endothelial cells 
was performed in formalin-fixed, routinely processed brain tumor biopsy 
material. MVP in glial neoplasms was compared with that in intracerebral 
metastatic carcinomas and in intracranial granulation tissue. On the basis of 
the degree of hyperplasia of hypertrophic cells in the microvascular wall, 
MVP was subjectively divided into mild, moderate, and glomeruloid 
(marked) proliferation. The relative contribution of vascular smooth muscle 
cells and endothelial cells to different degrees of MVP was estimated 
immunohistochemically using antibodies against α-smooth muscle actin and 
von Willebrand factor, respectively. Glomeruloid MVP occurred in 50% of 
the malignant glial neoplasms. Moderate MVP was found in most 
malignant gliomas and in some pilocytic astrocytomas. Glomeruloid MVP 
was present in peritumoral glial tissue in 4 out of 15 intracerebral meta­
static carcinomas, while only mild to moderate MVP was found within 
these tumors. In granulation tissue MVP was mild. In glomeruloid and 
moderate MVP vascular smooth muscle cells were more hypertrophic and 
more numerous than endothelial cells. The contribution of hypertrophic 
vascular smooth muscle cells to mild MVP was variable. MVP in glial 
neoplasms was generally not accompanied by a matrix of fibrous stroma 
but was directly embedded in glial tissue. The architecture of this MVP 
suggested "in situ" proliferation of microvascular cells without migration of 
these cells into the surrounding tissue. 
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Introduction 
Microvascular proliferation (MVP) is a well-known feature of malignant 
gliomas, especially of glioblastoma multiforme ' · 2 . On the basis of 
immunohistochemical studies, several components of the extracellular 
matrix in MVP in glial neoplasms have been described 3 1 2 . However, the 
precise origin and composition of the cellular components contributing to 
MVP remains unclear. 
MVP in glial neoplasms has been attributed to exuberant proliferation of 
endothelial cells 2 ' 3 · 1 4 . In contrast, several immunohistochemical studies 
have shown that not all cells in the wall of proliferating blood vessels in 
glial neoplasms are positive for endothelial cell markers 15'20. Pericytes 
i5.i6.i9
 v a s c u
i
a r
 smooth muscle cells '9, perivascular fibroblasts '6, and 
endothelial cells that do not express the endothelial cell marker Factor 
VIH-related antigen (FVIIIrAg) '6 have been suggested as contributing to 
this MVP. Using an α-smooth muscle actin (α-sm actin) antibody as 
marker for smooth muscle or pericyte differentiation, Schiffer et al. 20 
described that positive cells were present in glomeruloid blood vessels, but 
they only seemed to form a minority of the cells in these vascular structu­
res. Recently, Haddad et al. 21 described positive smooth muscle actin 
antibody staining in the majority of cells forming the glomeruloid 
structures in glioblastomas multiforme, suggesting that these structures are 
largely of vascular smooth muscle cell origin. 
In the present light microscopic and immunohistochemical study formalin-
fixed, routinely processed tissues were used allowing optimal 
morphological evaluation. MVP in glial neoplasms was compared with 
MVP in intracerebral metastatic carcinomas and in intracranial granulation 
tissue. Using antibodies against α-sm actin and von Willebrand factor 
(vWf) as markers for vascular smooth muscle cells/pericytes and 
endothelial cells, respectively, the relative contribution of these cells to 
different degrees of MVP was estimated. 
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Materials and Methods 
Case material 
Surgical material from the following cases was used: astrocytoma, η = 6; 
anaplastic astrocytoma, n = 5; glioblastoma multiforme, n=19; pilocytic 
astrocytoma, n=15; oligodendroglioma, n = 8; anaplastic oligodendrogli­
oma, η = 2; intracerebral metastatic carcinoma, η=20 (primary tumors: 5 
lung carcinomas, 4 breast carcinomas, 3 renal cell carcinomas, 1 colon 
carcinoma, 1 bladder carcinoma and 6 carcinomas of unknown origin); 
intracranial granulation tissue, n = 5 (3 cases of wall of subdural hematoma, 
1 organizing hematoma, 1 case of granulation tissue adherent to ventriculo­
atrial shunt). Autopsy material of normal brain (cerebral cortex and 
subcortical white matter, n=4) was used as normal control tissue. 
Astrocytic neoplasms were graded according to the three-tiered system 
proposed by Ringertz 22. All cases were reviewed by two neuropathologists 
and on the basis of the presence of diagnostic features the most 
representative tissue from each case was selected. 
Routine histology and immunohistochemistry 
Tissue was routinely fixed in neutral-buffered formalin and embedded in 
paraffin. Serial 5^m-thick sections of all cases were stained with 
hematoxylin-eosin (H&E), and with antibodies for a-sm actin and vWf. A 
mouse monoclonal antibody anti-a-smooth muscle actin (Sigma 
Diagnostics, St. Louis, Mo., USA) was used at a 1:400 dilution (lot no. 
031H4816) or 1:15000 dilution (lot no. M415). Anti-von Willebrand factor 
(Factor VIII) antibody is a rabbit polyclonal antibody, it was used at a 
1:600 dilution (DAKO Corporation, Santa Barbara, Calif., USA) or a 
1:300 dilution (CLB, Amsterdam, The Netherlands). Immunochemistry for 
a-sm actin and vWf was performed using the Autoprobe HI (Strep-Avidin-
Biotin) Universal Detection System (Biomeda Corporation, Foster City, 
Calif., USA). Deparaffinized tissue sections were dehydrated and washed 
in buffer. To remove endogenous peroxidase activity, sections were pre-
treated with 2% hydrogen peroxide in methanol for 5 min. The sections 
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were subsequently washed in buffer and treated with the enzyme pronase 
(Biomeda) for 10 min, followed by an incubation with commercially 
available tissue conditioner (Biomeda) for 10 min at 37°C. The sections 
were then washed in buffer and incubated for 60 min at 37°C with the 
primary antibodies against a-sm actin or vWf. Following a rinse in buffer, 
the biotinylated secondary antibody was applied for 30 min at 37°C, the 
sections were rinsed in buffer again and treated with the avidin-biotin 
complex for 30 min at 37°C. 3,3'-Diaminobenzidine tetrahydrochloride 
(DAB) (Sigma) or 3-amino-9-ethylcarbazole (AEC) (Biomeda) were used as 
chromogens. The sections were counterstained with hematoxylin. The 
lectin staining Ulex europaeus agglutinin type I (UEA-I; DAKO) was 
performed on the following cases: 5 glioblastomas multiforme, 2 pilocytic 
astrocytomas, 1 oligodendroglioma, 1 anaplastic oligodendroglioma, 2 
metastatic carcinomas, 2 cases of granulation tissue, and 2 control brains. 
The immunostaining procedure with peroxidase conjugated lectin UEA-I 
was similar to that described for a-sm actin and vWf, except that the 
sections were incubated with the lectin for 45 min at 37°C at a dilution of 
1:160. The sections were then briefly washed in PBS buffer and incubated 
with the peroxidase conjugated rabbit anti-UEA-I (DAKO) at a dilution of 
1:40 for 30 min at 37°C. 
Microvasculature analysis 
Microvascular proliferation was defined as hyperplasia of cells in the wall 
of capillaries, small arterioles and small venules. Hyperplastic 
microvascular cells were generally also hypertrophic. Proliferating blood -
vessels were subjectively divided into three categories on the basis of the 
degree of hyperplasia of cells in the microvascular wall in the H&E-stained 
slides: 
mild proliferation, hyperplasia of cells in the vessel wall with less than 
two continuous layers of hypertrophic cells around the vessel lumen (fig. 
la); moderate proliferation, hyperplasia of cells in the vessel wall with 
two or more continuous layers of hypertrophic cells around the vessel 
lumen (fig. lb); and glomeruloid (= marked) proliferation, hyperplasia 
and hypertrophy of cells in the vessel wall with formation of glomerulus-
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like structures containing three or more vessel lumina (fig. lc) 
FIG. 1. Different degrees of microvascular proliferation (MVP) in glial neoplasms, a mild, 
b moderate, and с glomeruloid. a-c H&E, χ 180 
In all cases MVP was evaluated and graded twice by one observer. A 
randomly selected 20% were reviewed by a second observer. No 
significant differences were found between these independent evaluations. 
The higher grade of MVP was assigned to those microvessels with a 
transition between different degrees of MVP. The relative contribution of 
vascular smooth muscle cells and endothelial cells to the three degrees of 
MVP was assessed by comparison in serial sections of the estimated 
number of a-sm actin-positive and vWf-positive cells respectively. 
Proliferating blood vessels in glial neoplasms were compared with those in 
intracerebral metastatic carcinomas and in granulation tissue. In the present 
study we did not focus on changes in the number of blood vessels. 
Results 
The occurrence of MVP in the material studied is summarized in table 1. 
Glomeruloid MVP occurred in 13 out of 26 malignant glial neoplasms 
(anaplastic astrocytomas, anaplastic oligodendrogliomas, glioblastomas 
multiforme) and in peritumoral neuroglial tissue in 4 out of 15 cases of 
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0 
3 
19 
6 
1 
1 
20 
14 
5 
0 
0 
2 
14 
3 
0 
1 
9 
7 
0 
0 
0 
1 
11 
0 
0 
1 
0 
4 
0 
0 
TABLE 1. MICROVASCULAR PROLIFERATION (MVP) IN BRAIN TUMORS, GRANULATION 
TISSUE, AND CONTROL TISSUE 
DEGREE OF MVP* 
n° with MVP / total n° of cases mild moderate glomeruloid 
GLIAL NEOPLASMS 
astrocytoma 0 / 6 
anaplastic astrocytoma 3 / 5 
glioblastoma multiforme 19/19 
pilocytic astrocytoma 6/15 
oligodendroglioma 1 / 8 
anaplastic oligodendroglioma 1 / 2 
INTRACEREBRAL METASTATIC CARCINOMA 
within tumor 20 / 20 
in pentumoral glial tissue** 14 / 15 
GRANULATION TISSUE 5 / 5 
CONTROL TISSUE, normal brain 0 / 4 
* for grading: see Materials and Methods 
** pentumoral glial tissue present in 15 out of 20 biopsies. 
intracerebral metastatic carcinoma (primary tumors: 2 renal cell 
carcinomas, 1 squamous cell carcinoma of the lung, 1 adenocarcinoma of 
unknown origin). Moderate and/or mild proliferation was present in all 
these cases, as well as in many other malignant glial neoplasms, and in 6 
out of 15 pilocytic astrocytomas. In other well-differentiated gliomas 
(astrocytomas, oligodendrogliomas) MVP was generally absent. Within 
intracerebral metastatic carcinomas mild to moderate MVP was found, but 
glomeruloid MVP was absent. In granulation tissue only mild MVP was 
found. 
The α-sm actin-positive cells in the vessel wall showed mostly a diffuse, 
sometimes a granular cytoplasmatic staining. The tunica media of arteries, 
arterioles, venules and veins was consistently and strongly α-sm actin 
positive. Tumor cells in glial neoplasms and in intracerebral metastatic 
carcinomas were always α-sm actin negative. In the vWf staining a 
granular, cytoplasmatic reaction was found in endothelial cells, while a 
weak, diffuse staining was seen in plasma and in perivascular connective 
tissue in some cases. Endothelial cells in proliferating vessels generally 
showed a more pronounced vWf-reaction than those in normal appearing 
microvessels, in which vWf staining was sometimes weak or absent. In 
normal brain tissue and in an oligodendroglioma the UEA-I staining gave a 
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crisp reaction product in the endothelial cells of the microvessels with 
accentuation of the cell membrane. In glial neoplasms and in granulation 
tissue the endothelial cells in proliferating blood vessels showed an incon­
sistent UEA-I staining and often were negative. 
F I G . 2. Endothelial cells (a,b) and vascular smooth muscle cells (c,d) in serial sections of 
glomeruloid MVP in glioblastoma multiforme, a von Willebrand factor (vWf), b vWf, с α-
smooth muscle actin (α-sm actin), d α-sm actin; a,c χ 190; b,d χ 320 
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The contribution of a-sm actin-positive cells to mild MVP was variable in 
glial neoplasms, intracerebral metastatic carcinomas and granulation tissue. 
In some of these vessels vWf-positive cells were predominant, while in 
other vessels the a-sm actin-positive cells were more prominent. In 
glomeruloid and moderate MVP vWf-positive cells were found in one layer 
immediately surrounding the recognizable vessel lumina. These cells 
showed varying degrees of hypertrophy. In some cases of glomeruloid 
MVP the lumina were hard to find. The majority of the remaining cells in 
vessels with florid MVP did not stain for vWf and were variably, but con­
vincingly, a-sm actin positive. These cells were often plump and rounded, 
and outnumbered the vWf-positive cells in these vessels (fig. 2). 
In all cases of granulation tissue, in 18 out of 20 intracerebral metastatic 
carcinomas, and in 3 out of 55 glial neoplasms (3 glioblastomas multifor­
me) areas of reactive fibrous tissue were present with a-sm actin-positive, 
stellate or spindle-shaped cells showing variable cytoplasmic extensions. 
Some of these cells showed a very close, topographical relation to a-sm 
actin-positive cells in the vessel wall (fig. 3). 
F I G . 3. Fibrous stroma in 
glioblastoma multiforme in which 
fibroblast-like, a-sm actin-positive 
cells show close topographical 
relationship to vascular smooth 
muscle cells, a-sm actin, χ 175 
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Discussion 
Florid microvascular proliferation (MVP) is a remarkable and well known 
feature of malignant glial neoplasms, especially of glioblastomas 
multiforme '2 . In the older literature this MVP was attributed to exuberant 
multiplication of endothelial cells '3 ' \ or proliferation of adventitial cells 
23
. In ultrastructural studies of MVP in glial neoplasms the proliferating 
cells surrounded by basement membrane in the wall of proliferating 
microvessels have been considered as incorporated neoplastic cells 2 \ 
adventitial histiocytes u, endothelial cells 2627 and smooth muscle cells or 
pericytes 28. 
In 1981 Weller et al. 15, using an immunoperoxidase technique, noted that 
FVIIIrAg was present in only some of the cells in the glomeruloid capillary 
tufts in malignant gliomas. Similar results were obtained by several other 
authors using FVIIIrAg or UEA-I as a marker for endothelial cells 162°, 
and a contribution of pericytes or vascular smooth muscle cells to MVP in 
gliomas was proposed 15-16·19. Schiffer et al. 20 stained malignant gliomas for 
a-sm actin and FVIIIrAg. They observed very few a-sm actin-positive 
cells in small vessels with endothelial proliferation, while in glomeruloid 
structures a-sm actin-positive cells were more abundant but still formed a 
minority. Furthermore, many cells "far" from lumina in large glomeruli 
were negative for a-sm actin and for FVIIIrAg. Recently, Haddad et al. 2I 
described that the majority of cells forming the glomeruloid vascular struc-
tures in glioblastoma multiforme stained positively with both muscle spe-
cific a-actin and a-sm actin antibodies. 
The present study corroborates the findings of Haddad et al. 2I and 
demonstrates that not only in glioblastomas, but also in other glial 
neoplasms and in or around intracerebral metastatic carcinomas, the 
majority of the mural vWf/FVIIIrAg-negative cells in moderate and 
glomeruloid MVP are a-sm actin positive. Antibodies for a-sm actin are 
described as a marker for both vascular smooth muscle cells and pericytes 
29
·
30
. Since these cells are probably closely related 31, in the present study 
we shortly refer to the a-sm actin-positive cells as vascular smooth muscle 
cells. Although a-sm actin positivity has been described in cultured rat, 
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murine and porcine endothelial cells as well 32'33, to the best of our 
knowledge a-sm staining has not been demonstrated in human endothelial 
cells in tissue sections. We agree with Haddad et al. 21 that the 
predominant cell type in florid MVP in glial neoplasms has the 
immunohistochemical phenotype of vascular smooth muscle cells, in spite 
of the widely used term "endothelial proliferation". Still, the contribution 
of endothelial cells to florid MVP might be substantial M. Unlike the 
findings of Schiffer et al. 20, in our study the cells in the periphery of the 
glomeruloid blood vessels were also a-sm actin positive. 
UEA-I has been recommended as a marker for endothelial cells in 
formalin-fixed, routinely processed brain tumor tissue '8. In our hands the 
vWf-staining was much more reliable in detecting endothelial cells in 
MVP. 
The pathogenesis of MVP in glial neoplasms is obscure. In 1958 Feigin и 
suggested that a diffusable factor might play a role. Many angiogenic 
factors have been characterized during the last 15 years 3 5 · 3 6 . Production of 
angiogenic factors has been found in tumor cells and cell cultures of human 
glial neoplasms 37~43. Especially since receptors for some of these 
angiogenic factors have been demonstrated on cells in the wall of 
hyperplastic capillaries 41,42, these factors may very well contribute to MVP 
in a paracrine fashion. 
Comparison of MVP in glial tumor tissue with that in and around 
intracerebral metastatic carcinomas and in granulation tissue was of special 
interest. Within intracerebral metastatic carcinomas and in granulation 
tissue glomeruloid MVP was absent and MVP was generally accompanied 
by proliferation of a-sm actin-positive myofibroblasts in a matrix of fibrous 
stroma. This myofibroblastic proliferation was found in only 3 out of 55 
glial neoplasms (3 glioblastomas multiforme). Myofibroblasts were 
originally described as modulated fibroblasts *·, but smooth muscle cells 
and pericytes must also be considered as progenitor cells of myofibroblasts 
4 5
·
4 6
. In our study a close topographical relationship was found between 
some myofibroblasts and vascular smooth muscle cells, suggesting 
migration of these microvascular cells into the surrounding tissue. 
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A recent immunohistochemical study showed positive muscle-specific a-
actin and a-sm actin staining of malignant spindled and polygonal cells in 
the sarcomatous component of ghosarcomas, indicating that the develop-
ment of this component is the result of malignant transformation of 
proliferating vascular smooth muscle cells or myofibroblasts 47 In some 
earlier immunohistochemical studies the same origin of spindle-cell 
proliferation in glial neoplasms was suggested 4844, in other studies the 
sarcomatous component was thought to be (at least partly) derived from 
endothelial cells 175°, fibroblasts or pluripotent adventitial cells 51, or glial 
cells 52 
In the present study glomeruloid MVP was only found in malignant 
gliomas and in glial tissue surrounding intracerebral metastatic carcinomas 
In these tissues, proliferating microvessels were generally directly 
embedded in glial tissue, the proliferating cells being confined to the wall 
of existing vessels A lack of directional microvascular growth in gliomas 
has also been suggested by Weller et al on the basis of the coiled, looping 
nature of capillaries in these tumors '5 This concept of "in situ" prolifer-
ation of cells m the vessel wall might be supported by ultrastructural 
studies of the cast of tortuous and enlarged vascular structures of a human 
malignant glioma 53 and of a rat glioma 54 
A possible reason for the lack of migration of microvacular cells in glial 
tissue might be a (relative) absence of an adequate scaffold for migration in 
this tissue It has been postulated that in granulation tissue and in tumor 
stroma a scaffold for migratory cells is formed by deposition of a 
provisional extracellular matrix of especially fibrin and fibronectin, leaking 
from damaged blood vessels 55 In several immunohistochemical studies 
only a faint staining for fibronectin was occasionally present in between the 
glial tumor cells, while a strong staining for fibronectin was generally 
found in and around the microvascular walls 3 610 '7 In glial neoplasms the 
leakage of macromolecules contributing to a provisional extracellular 
matrix might thus be limited 
In 1972, a quantitative method for histological grading of tumor 
angiogenesis, the "Microscopic Angiogenesis Grading System" (MAGS) 
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was published 56 The MAGS score is based on three parameters 
vasoprohferation, endothelial cell hyperplasia, and endothelial cytology 
Glioblastomas appeared to be on the "endothelial-nch" end of the 
spectrum The high MAGS score in glioblastomas led to the suggestion that 
these "endothelial-nch" tumors depend more on extensive neovasculariza-
tion for their continued growth than "endothehal-poor" tumors 56 Anti-
angiogenic drugs were therefore considered as a potential therapy for 
especially malignant gliomas 5758 More capillary surface area is 
undoubtedly added by reduplication of capillary lumina in the glomeruloid 
blood vessels in glial neoplasms, but the functional importance of this type 
of neovascularization is not clear It is also not clear to what extent 
gliomas, especially the infiltrating cells at the margins of these tumors, 
depend on neovascularization It has been suggested that m gliomas the 
tumor spreads using existing vessels rather than being supplied by new 
ones 20 
In summary, the present study shows that the contribution of vascular 
smooth muscle cells to moderate and glomeruloid MVP in glial neoplasms 
and in intracerebral metastatic carcinomas is more prominent than that of 
endothelial cells The contribution of vascular smooth muscle cells to mild 
MVP in these tumors is variable The architecture and composition of 
especially glomeruloid MVP in glial neoplasms suggests "in situ" 
proliferation of cells in the préexistent vessel wall without migration of 
these cells into the surrounding tissue The remarkable morphology of 
MVP in glial neoplasms might be due not only to the production of an-
giogenic factors but also to the lack of an adequate scaffold for migration 
of microvascular cells in these tumors 
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Summary 
Although florid microvascular proliferation (MVP) in glioblastoma 
multiforme (GBM) has long been considered as proliferation of endothelial 
cells (ECs), recent immuno-light microscopic studies demonstrated many 
α-smooth muscle actin (a-sm actin) positive cells in this MVP, suggesting 
a major contribution of pericytes and/or vascular smooth muscle cells 
(VSMCs) Under certain culture conditions, however, a-sm actin 
expression has also been described in ECs In order to further investigate 
to what extent pencytes/VSMCs participate in MVP in GBMs, we 
performed an immunohistochemical study at both the light- and electron 
microscopic level with anti-a-sm actin, with an antibody against ECs (EN-
4) and with an antibody recently described to react with "activated" 
pericytes in conditions with neovascularization (anti-High Molecular 
Weight-Melanoma Associated Antigen, anti-HMW-MAA) In this detailed 
study of MVP in GBM, two distinct cell types could be recognized on the 
basis of a consistent ultrastructural localization and immunophenotype ECs 
and pericytes/VSMCs, no transitional forms were found between these two 
cell types The contribution of pencytes/VSMCs to MVP in GBM was 
extensive and already present in many delicate tumor capillaries, suggesting 
not only an essential, but also an early role of these cells in this type of 
tumor angiogenesis 
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Introduction 
Folkman in 1971 hypothesized that solid tumors are dependent on 
angiogenesis for sustained growth ' 2 In glioblastoma multiforme (GBM), 
the most malignant human glial neoplasm, florid microvascular 
proliferation (MVP) is a remarkable and well known feature 3 4 Because of 
this florid MVP, of which the most prominent form was called glomeruloid 
MVP 5, it has been suggested that GBMs depend more on extensive 
neovascularization for continued growth than "endothelial-poor" tumors 
and that anti-angiogenic treatment is a potential therapy 6 8 Elucidation of 
the pathogenesis and biological significance of florid MVP in GBMs is 
therefore important since it will not only lead to a better understanding of 
angiogenesis and malignancy in glial tumors ', but also may provide the 
basis for a rational treatment 
Florid MVP in GBMs has long been considered as proliferation of 
endothelial cells (ECs) as is apparent in the common designation 
"endothelial proliferation" 45 l° Two recent, immuno-light microscopic 
studies on paraffin-embedded tissue of GBMs showed, however, that many 
abluminal cells participating in glomeruloid MVP were α-smooth muscle 
actin (a-sm actin) positive " u Antibodies for a-sm actin were described 
as markers for both pericytes and VSMCs ' 3 1 4 , two cell types that are 
closely related '5 '7 Therefore, a major contribution of pencytes/VSMCs to 
florid MVP in glial neoplasms was suggested However, since a-sm actin 
expression has also been described in ECs under certain culture conditions 
18 2\ the possibility remains that the a-sm actin positive cells in florid MVP 
in GBMs are in fact modified ECs that migrated to an abluminal position 
The present study further characterizes the nature of the cells contributing 
to this MVP by investigating at both the light- and electron microscopic 
level the distribution of a-sm actin, of a marker for ECs (EN4), and of a 
marker for "activated" pericytes (anti-High Molecular Weight-Melanoma 
Associated Antigen, anti-HMW-MAA) in the microvasculature of GBMs 
EN-4 was previously described as a marker for ECs in cryostat sections of 
both normal and neoplastic human tissues, the pericytes in these tissues 
being EN-4 negative 2 4 2 5 HMW-MAA is a large chondroitin sulphate 
proteoglycan which was demonstrated by means of immuno-electron 
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microscopy on the cell membrane of pericytes (but not on adjacent ECs) in 
conditions with neovascularization (1 e tumors and granulation tissue) The 
molecule is also synthesized by pericytes in culture which carry it on cell 
membrane microspikes In normal human tissues, HMW-MAA is barely 
detectable in capillaries, while VSMCs of larger blood vessels show a 
variable HMW-MAA-expression ^ 2 7 
Materials and Methods 
Materials 
For the immuno-light microscopic study, snap frozen tissue was used of 
surgical material (supratentonal GBMs, η = 18, supratentonal diffuse 
astrocytomas, η = 3, normal brain tissue, η = 4) and of normal brain 
obtained by autopsy (n = 5, post mortem delay less than 6 hours) The 
normal brain tissue obtained by surgery was removed for technical reasons 
from the neighbourhood of a brain tumor (n — 3) and a vascular 
malformation (n = 1), only after very careful microscopic evaluation this 
material was considered to be histologically normal The autopsy material 
was derived from patients who had died of non-cerebral disorders 
Additionally, paraffin-sections of formalin-fixed material from 12 GBMs 
and 5 normal brains were used for immuno-light microscopy For lmmuno-
electron microscopy, small fragments of 3 GBMs were promptly fixed in 
2% paraformaldehyde in Sorensen buffer (pH = 7 4) Histological typing 
of the tumors was performed on hematoxyhn-eosin stained sections of 
formal in-fixed, paraffin-embedded tissue according to the revised WHO-
classification 28 Sections of the snap frozen and paraformaldehyde-fixed 
tissues were stained with the monoclonal antibodies (MoAbs) EN4 (Sanbio, 
Uden, The Netherlands), anti-HMW-MAA 2 6 2 7 , and anti-a-sm actin (Sigma 
Chemical Co, St Louis, MO, USA), while paraffin-sections of GBMs and 
normal brains were also stained with anti-a-sm actin Optimal working 
dilutions of the MoAbs were determined previously on positive controls 
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Immuno-light microscopy 
In brief, serial 4 μΓΠ-sections of snap frozen tissue were air-dried, fixed in 
acetone for 10 minutes at room temperature (RT) and then incubated with 
the Mo Abs at RT for 60 minutes. Mo Abs were diluted in phosphate-
buffered saline (PBS, pH = 7.4) containing 1% bovine serum albumin 
(BSA). After rinsing the sections three times with PBS, the primary Abs 
were detected by incubation at RT with a peroxide-conjugated rabbit-anti-
mouse Ab (Dakopatts/ITK, Glostrup, Denmark), followed by three wash 
steps with PBS and incubation with 5 mg/ml DAB (3,3'-Diaminobenzidine-
tetrahydrochloride, Sigma Chemical Co). Then the sections were rinsed in 
tap water, treated for 5 min. with a 0.9% NaCl solution with 0.5% CuS04 
and counterstained with hematoxylin-Mayer. Finally, the sections were 
again rinsed in tap water, dehydrated, and mounted with permount (Boom 
b.v., Meppel, The Netherlands). Negative controls consisted of incubations 
replacing the primary Ab with PBS-BSA. The anti-a-sm actin staining of 
formalin-fixed, paraffin-embedded tissue was performed as described 
previously 12. Immunoreactivity was semi-quantitatively assessed in three 
categories of microvessels (delicate capillaries, arterioles/venules, and 
florid MVP) according to the extent of the staining (most = half or more, 
some = less than half, or none = none of the vessels in a category 
positive) and to the intensity of the staining (marked, weak, or negative). 
Florid MVP was defined as hyperplasia of cells in the microvascular wall 
with two or more continuous layers of hypertrophic cells around the vessel 
lumen and with the formation of tortuous, often glomerulus-like vascular 
structures. The microvascular staining in GBMs was compared with the 
staining in glial/glioma tissue without florid MVP (normal brain and low 
grade, diffuse astrocytoma). The slides were evaluated by two observers 
(PW, DJR), no significant differences existed between these independent 
evaluations. 
Immuno-electron microscopy 
A pre-embedding immunoperoxidase technique was used to demonstrate the 
ultrastructural distribution of the staining with the MoAbs. Surgical 
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material with a maximum size of 4x6x2 mm was promptly fixed for 4 
hours at RT in freshly prepared 2% paraformaldehyde in Sörensen buffer 
(pH 7.4). After washing at RT for 1 hour in PBS and for 45-60 minutes in 
2.3 M sucrose solution, the tissue was immediately frozen in liquid 
nitrogen and stored at -196 °C. On a cryomicrotome (Micron, Heidelberg, 
Germany) 30 μπι sections were cut at -20°C and washed in PBS at RT for 
1.5 hours. These sections were incubated overnight with the first Ab at 
4°C in a PBG buffer (PBS + 0.5% BSA (Aurim, Wageningen, The 
Netherlands) + 0.1 % gelatin (Merck, Darmstadt, Germany), pH of PBG 
buffer = 7.4) using a rotary shaker. After washing in PBS for 1.5 hours, 
the sections were incubated at RT for 1.5 hours with a peroxide-conjugated 
rabbit-anti-mouse and/or swine-anti-rabbit Ab (Dakopatts/ITK) at appro­
priate dilution in PBG. Control sections were incubated with the second 
antibodies alone. After extensive washing for 1.5 hours at RT in PBS, the 
sections were incubated in a 5 mg/ml DAB solution in PBS, containing 3 
mg/ml ammonium-nickel-sulfate-hexahydrate (FLUKA 09885, Buchs, 
Switzerland). The sections were then developed for 8-10 min in the same 
solution containing 0.01% H202 (30%). The reaction was terminated by 
rinsing with tap water. The sections were post-fixed in 1 % Osmium 
tetroxide for 5 min at RT, dehydrated and embedded in Epon 812. One 
micron sections were cut for light microscopy and stained with toluidin 
blue. Ultrathin sections were cut with a diamond knife (Drukker, Cuyk, 
The Netherlands) on an ultramicrotome (Reichert Jung, Vienna, Austria). 
The ultrathin sections were contrasted for 1 min. with uranyl-acetate 3% 
and examined and photographed with a JEOL 1200 EX/II electron 
microscope (Tokyo, Japan) at 40 KV. 
Results 
Immuno-light microscopy 
Florid MVP was present in cryostat-sections of 11 out of 18 GBMs and in 
paraffin-sections of 9 out of 12 GBMs. Furthermore, all GBMs contained 
many delicate capillaries with normal appearance or at the most mild MVP 
in the form of mild hyperplasia and/or hypertrophy of microvascular cells. 
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In normal brain and in astrocytomas MVP was absent. The results of the 
immuno-light microscopic study are summarized in table 1. 
TABLE 1. RESULTS OF LIGHT MICROSCOPIC, IMMUNOHISTOCHEMICAL STUDY OF 
GLIAL/GLIOMA MICROVASCULATURE 
GBM 
normal brain/ 
astrocytoma 
capillaries 
florid MVP 
arterioles/ 
venules 
capillaries 
arterioles/ 
venules 
EN-4 
+ -t 
+ + 
+ + 
+ + 
+ + 
HMW-MAA 
-, + , + + 
+ + 
+ + 
+ 
a-sm actin 
(FS) 
- ( + ) 
- ( + ,+ +) 
+ + 
+ + 
a-sm actin 
(PS) 
-, + , + + 
-, + , + + 
+ + 
+ + 
Summary of staining results in glioblastoma multiforme (GBM) versus normal brain and 
low grade diffuse astrocytoma, FS = frozen sections, PS = paraffin sections; - = negative; 
+ = weak staining; + + = marked staining; between brackets: staining pattern in minority 
of cases. 
In normal brain, astrocytomas, and GBMs the microvessels (including 
vessels showing MVP) were generally strongly EN-4-positive. The EN-4-
staining was present in the form of a fine-granular staining of one layer of 
cells immediately around the recognizable vessel lumina, consistent with 
staining of ECs (fig. la,e). In GBMs, a marked, fine granular HMW-
MAA-staining of many cells in both florid MVP and in more delicate 
capillaries was found (fig. lb,f). In the a-sm actin staining on cryostat-sec-
tions, florid MVP and delicate capillaries in GBMs were often negative, 
only occasional cells in these microvessels showed cytoplasmic staining 
(fig. lc,g). In paraffin-sections of GBMs, however, many cells in florid 
MVP and scattered cells in delicate capillaries were strongly a-sm actin 
positive (fig. ld,h). Compared to the HMW-MAA-staining in frozen 
sections of GBMs, the a-sm actin-staining of delicate capillaries in paraffin 
sections was less abundant. Capillaries in normal brain and in astrocytomas 
were generally HMW-MAA- and a-sm actin-negative, only in one 
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astrocytoma and one biopsy of histologically normal brain some capillaries 
showed a marked or weak HMW-MAA-staining, respectively. In both 
cryostat- and paraffin-sections arterioles and venules were consistently and 
strongly a-sm actin-positive, in the HMW-MAA-staining most of these 
vessels were weakly positive in normal brain and markedly positive in 
GBMs. The localization of the HMW-MAA- and a-sm actin-staining in 
arterioles and venules was consistent with staining of VSMCs (fig. lf,g). 
The normal and neoplastic glial tissue was negative for EN-4 and a-sm 
actin, while some GBMs showed a weak HMW-MAA-staining of the glial 
tissue. The complementary staining pattern in microvessels for EN4 and 
for HMW-MAA/a-sm actin suggested staining of ECs and pericytes/ 
VSMCs, respectively, but the exact cellular localization of these stainings 
could not be determined with certainty by light microscopy. 
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FIG. 1. Immuno-light microscopy of glomeruloid microvascular proliferation (a-d) and of 
delicate capillaries (e-h) in glioblastoma multiforme on serial frozen sections (a-c; e-g) and 
on paraffin sections (d,h); in e-g arteriole in lower half of the picture; a,e. EN-4; b,f. 
HMW-MAA; c,d,g,h. a-sm actin; a-h: original magnification x200, counterstaining with 
hematoxylin. The early and extensive contribution to microvascular proliferation in 
glioblastoma multiforme of not only endothelial cells, but also of pericytes and/or vascular 
smooth muscle cells is indicated by the EN-4-staining and the HMW-MAA- and a-sm actin-
staining, respectively. Note the relative lack of microvascular a-sm actin staining in frozen 
sections compared to paraffin sections. 
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Immuno-electron microscopy 
Although the manipulation of GBM tissue during operation and the prepa­
ration of this material for immuno-electron microscopic study resulted in a 
reduction of the ultrastructural preservation of the tissue, the microvascular 
structures were clearly recognizable. In both florid MVP and more delicate 
capillaries extensive and strong EN-4-staining was found at the luminal 
membrane of the cells lining the vessel lumina, including the membrane of 
the villous processes formed by these cells and projecting into the lumen. 
The abluminal membrane of the cells lining the vessel lumina showed a 
variable EN-4-staining. The remaining cells in the vessel wall were EN-4-
negative (fig. 2a,d). 
FIG. 2. Immuno-electron microscopy of glomeruloid microvascular proliferation (a-c) and 
of delicate capillaries (d-f) in glioblastoma multiforme; a,d. EN-4; b,e. HMW-MAA; c,f. 
a-sm actin; asterisk = microvascular lumen; E = endothelial cell; Ρ = pericyte/vascular 
smooth muscle cell; a-c: bar = 5 μπι; d-f: bar = 3 μιτι. In both florid microvascular 
proliferation and delicate capillaries in glioblastoma multiforme two distinct cell types can 
be recognized on the basis of ultrastructural localization and immunophenotype: endothelial 
cells (luminal cells; EN-4-positive; HMW-MAA- and a-sm actin-negative) and 
pericytes/vascular smooth muscle cells (abluminal cells; EN-4-negative; variably HMW-
MAA- and a-sm actin-positive). 
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After HMW-MAA- and a-sm actin-staining, in florid MVP the cells lining 
the vessel lumina were negative, but the surrounding, abluminal cells and 
their processes were variably and often strongly positive In these cells, a 
mostly diffuse, cytoplasmic staining was found with anti-a-sm actin, while 
the HMW-MAA-staining was located at the cell membrane and sometimes 
extending in the extracellular matrix immediately surrounding these cells 
(fig. 2b,c) Many cells in the wall of more delicate capillaries in GBMs 
showed a similar staining pattern for HMW-MAA and a-sm actin (fig. 
2e,f) In some of the abluminal cells in these delicate microvessels only a 
focal, submembranous instead of diffuse, cytoplasmic staining for a-sm 
actin was found (fig. 2f) 
Discussion 
Although light microscopically the exact cellular location of the 
immunohistochemical microvascular staining could not be determined with 
certainty, the complementary staining pattern with EN-4 on the one hand 
and for HMW-MAA and a-sm actin on the other suggested staining of ECs 
and pericytes/VSMCs, respectively EN-4 appeared to be a reliable marker 
for microvessels in snap frozen tissue of both normal and neoplastic glial 
tissue As in previous studies on paraffin sections " l2, a substantial 
contribution of a-sm actin-positive cells to florid MVP and more delicate 
capillaries was found in GBMs, while capillaries in astrocytomas and 
normal brain were a-sm actin-negative The hypothesis that the a-sm actin-
positive cells in MVP in GBM are activated pericytes or VSMCs rather 
than ECs is corroborated by the extensive presence of HMW-MAA-
positive cells in these microvessels For unknown reasons a less extensive 
a-sm actin-staining of MVP (but not of arterioles and venules) was found 
in snap frozen tissue of GBMs than in formalin-fixed, paraffin-embedded 
tissue and in paraformaldehyde-fixed tissue of these tumors 
The present immuno-electron microscopic study substantially contributes to 
the unequivocal characterization of the cells participating in MVP in 
GBMs On the basis of localization and immunophenotype, two cell types 
could ultrastructurally be recognized m both florid MVP and more delicate 
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capillaries in these tumors: ECs (lining the vessel lumina; EN4-positive; 
HMW-MAA- and a-sm actin-negative), and pericytes/VSMCs (abluminal 
cells; EN4-negative; variably HMW-MAA- and a-sm actin-positive). We 
did not find transitional forms between these cell types. Further 
characterization of the microvascular cells was difficult because of the 
reduced ultrastructural preservation of the tissue used for immuno-electron 
microscopy. Since both (activated) pericytes and VSMCs can be HMW-
MAA- and a-sm actin-positive, these cells could not be discriminated in 
the abnormally configurated vascular structures of florid MVP. However, 
in delicate tumor capillaries the position and caliber of the a-sm actin- and 
HMW-MAA-positive cells demonstrated that in these vessels the positive 
cells are pericytes instead of VSMCs. This finding strongly suggests that 
activation of pericytes is an early event in MVP in GBM. The focal, 
submembranous instead of diffuse, cytoplasmic a-sm actin-staining 
observed by immuno-electron microscopy in some of these pericytes 
probably represents a relatively early phase in the activation of these cells. 
While in GBMs a-sm actin and HMW-MAA reactivity was present in 
many delicate capillaries, such staining was generally absent in capillaries 
of normal brain and low-grade astrocytoma. Only in one of the three 
examined astrocytomas some capillaries were HMW-MAA-positive, 
suggesting that activation of pericytes precedes MVP in the course of 
malignant progression of these neoplasms. A larger series of diffuse 
astrocytic neoplasms should be investigated to assess the prognostic 
significance of the a-sm actin- and/or HMW-MAA-staining of delicate 
capillaries. In the present study it was noted that the expression of HMW-
MAA in delicate capillaries of GBMs was more extensive than that of a-sm 
actin. This phenomenon has been described before 26 and indicates that in 
GBMs HMW-MAA may be an earlier or a more sensitive marker for 
activation of pericytes than a-sm actin. 
Angiogenesis is regulated by stimulatory and inhibitory factors that are able 
to modulate the migration and/or proliferation of microvascular cells 2931. 
Like angiogenesis in other tumors, florid MVP in GBMs has been 
attributed to the increased production and/or release of angiogenic growth 
factors, of which Vascular Endothelial Growth Factor / Vascular 
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Permeability Factor (VEGF/VPF), Platelet-Derived Growth Factor 
(PDGF), and acidic and basic Fibroblast Growth Factor (a- and b-FGF) 
have been studied the most intensively 32. While the mitogenic activity of 
VEGF is restricted to ECs, PDGF and FGF are mitogenic for a spectrum 
of cells, including SMCs and ECs 31. Since florid MVP in GBM used to be 
regarded as (largely) endothelial in nature, the demonstration of PDGF 
(and its receptor) and of FGF in this MVP prompted some authors to 
consider these factors as important stimulators of EC proliferation in 
GBMs 33"36. The early and extensive contribution of pericytes/VSMCs to 
MVP in GBMs indicates that these cells are also significantly stimulated by 
angiogenic factors. In fact, as discussed by Haddad et al. ", PDGF is more 
likely to stimulate the proliferation of pericytes/VSMCs than of ECs. 
Similarly, in human healing wounds and colorectal adenocarcinomas 
microvascular pericytes rather than ECs were found to express PDGF-
receptor 37. 
Several roles have been suggested for pericytes in the normal 
microvasculature, such as regulation of EC proliferation, of vascular 
permeability, and of vessel diameter 15~17. The role of pericytes/VSMCs 
during angiogenesis is unclear 38. In vitro studies demonstrated that VSMCs 
and pericytes can inhibit proliferation of ECs by a mechanism that requires 
contact or close proximity between the two cell types, the inhibition being 
mediated by Transforming Growth Factor-ßl (TGF-ßl) 3941. TGF-ßl has 
also been shown to mediate the increased expression of a-sm actin in 
cultured human brain pericytes 27, cells that are generally a-sm actin 
negative in normal brain n . The increased a-sm actin-expression of 
pericytes in GBMs might indicate a contractile role of these cells 13. 
In conclusion, the present immuno-light and immuno-electron microscopic 
study shows a substantial contribution of microvascular cells with the 
ultrastructural localization and immunophenotype of pericytes/VSMCs to 
both florid and mild MVP in GBMs. Thus, this study not only corroborates 
the findings of previous immuno-light microscopic studies suggesting 
extensive participation of pericytes/VSMCs to florid MVP in GBMs, but 
also indicates an early role of these cells in this type of tumor 
angiogenesis. The precise role of pericytes/VSMCs during angiogenesis is, 
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however, largely obscure and warrants further investigation. 
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Summary 
Monoclonal antibody (MoAb) RC38 recognizes a human renal antigen of 
160 kd recently identified as human Aminopeptidase-A (ΑΡΑ, E С 
3 4 117) This ectoenzyme is able to selectively hydrolyze N-terminal 
glutamyl and aspartyl residues from oligopeptides By enzyme 
histochemistry APA activity has also been localized in the microvessels of 
all organs in animals and man The purpose of this study was to investigate 
the distribution of human APA as recognized by MoAb RC38 in the 
microvasculature of normal human tissues and pathological conditions 
associated with neovascularization Unexpectedly, in normal tissues 
vascular staining with MoAb RC38 was generally weak and often absent, 
while in tumors, granulation tissue and chronic synovitis marked 
microvascular staining was demonstrated By immuno-electron microscopy 
the antigen was found on the cell membrane of activated pericytes and their 
processes in the tumor vasculature RC38 expression could not be detected 
on cultured human endothelial cells or pericytes Our observations suggest 
that pericyte expression of a subtype of APA (as recognized by MoAb 
RC38) is markedly enhanced in pericytes in the vasculature of tumors and 
wound healing tissue as compared to normal resting tissues This provides 
further evidence of the altered state of pericytes in these conditions 
Pericyte APA may be involved in the metabolism of biologically active 
oligopeptides during neovascularization supporting a regulatory role of 
pericytes in this process In addition, MoAb RC 38 may be useful as a 
marker of pericyte activation in tissue sections 
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Introduction 
The role of pericytes in the process of angiogenesis remains controversial '' 
3
. Based on in vitro studies, some authors attribute an inhibiting influence 
of these cells on the proliferation of endothelial cells in the end stage of the 
angiogenic response 1 4 5 . On the basis of morphological studies 6~10, others 
have suggested that pericytes already play an active role in the initial stages 
of neovascularization. 
Early ultrastructural reports on angiogenesis in situ demonstrated pericytes 
with plump cell bodies and an increased number of cell organelles near 
angiogenic stimuli, signs that were attributed to cellular "activation" " 1 4 . 
In recent reports, we have demonstrated that such activated pericytes occur 
in increased numbers in microvessels in tumors and granulation tissue 7 · 8 1 5 . 
Furthermore, these cells were found to have enhanced expression of a 
chondroitin sulphate proteoglycan (HMW-MAA) that was previously 
implied in the metastatic potential and migration of melanoma cells 7 '5. 
From these studies we concluded that activated pericytes are present 
already at the onset of angiogenesis and that their altered phenotype may 
enable them to migrate or perform other specialized functions. 
In the present study we have focused on the expression in pericytes of the 
ectoenzyme Aminopeptidase A (Glutamyl Amino peptidase, APA, E.C. 
3 4.11.7) as recognized by monoclonal antibody RC38 '6. APA is able to 
selectively hydrolyse N-terminal glutamyl and aspartyl residues from 
oligopeptides '72°. Angiotensin II, a potent constrictor of blood vessels, is 
an important substrate of the enzyme. APA activity has been demonstrated 
by enzyme histochemistry in epithelial brush borders in the kidney and 
small intestine and in the microvasculature of all organs in the rat, guinea 
pig and man 1 7 · 2 1 . The latter was interpreted as endothelial reactivity. 
However, a recent immunohistochemical study of APA in the rat brain 
suggested that vascular staining is solely based on expression by pericytes 
20 
The RC38 antibody was previously described as recognizing a renal 
antigen '6. Its distribution in the kidney and other characteristics suggested 
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similarity to Mo Ab S4 21, which recognizes a renal 160 kD glycoprotein 
that recently was identified as human АРА 23. 
In this report we demonstrate by immunoprecipitation studies that MoAb 
RC38 also recognizes human APA and we report on the tissue distribution 
of human APA as recognized by MoAb RC38 in normal tissues and in 
pathological conditions associated with angiogenesis. We found marked 
staining of microvessels in tumors and granulation tissue compared to weak 
or absent staining in vessels of normal organs. This appeared to be based 
on staining of activated pericytes as evidenced by immuno-electron 
microscopic studies. We conclude that activated pericytes express a form of 
APA that may be involved in the metabolism of biologically active peptides 
during angiogenesis. 
Materials and Methods 
Tissue samples 
Samples from normal and pathological human tissues were obtained from 
fresh surgical specimen and from patients who were autopsied within 8 
hours after death. Included in the study were normal tissues, neoplasms, 
granulation tissues, and vasoformative tumors (table 1). All tissues were 
snap-frozen and stored at -70 °C. For immuno-electron microscopy, 
selected tissue samples were promptly fixed in 2% paraformaldehyde in 
Sörensen phosphate buffer after surgical removal. 
Cultured cells 
Microvascular endothelial cells were isolated from human foreskin and 
cultured in Dulbecco's minimal essential medium supplemented with 40% 
normal human serum 24. Human umbilical vein endothelium, fibroblasts, 
human brain pericytes and a renal carcinoma cell line (SK-RC-1) were 
isolated and grown in culture as described elsewhere 724. Different passages 
were used for immunoperoxidase staining of cytospin preparations. 
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TABLE 1. TISSUES USED FOR IMMUNOHISTOCHEMISTRY 
Normal tissues 
skin 
esophagus 
jejunum 
colon 
pancreas 
liver 
spleen 
lymph node 
tonsil 
thymus 
thyroid 
lung 
kidney 
ovary 
testis 
cerebral cortex 
cerebellum 
skeletal muscle 
mamma 
placenta 
Number 
6 
1 
1 
4 
4 
2 5 
4 
2 
4 
2 
1 
4 
1 
1 
5 
2 
2 
3 
4 
Pathological tissues 
Vasoformative tumors 
hemangioma 
angiosarcoma 
pyogenic granuloma 
Other tumors 
breast neoplasms 
colon neoplasms 
neuroblastoma 
sarcoma 
melanoma 
meningioma 
glioblastoma multiforme 
hemangiopericytoma 
Wound healing 
decubitus lesion 
burn wound 
chronic synovitis 
Num 
2 
1 
2 
16 
12 
1 
4 
4 
2 
8 
1 
6 
4 
4 
Immunoperoxidase staining 
Air-dried frozen tissue sections and culture coverslips were fixed with 
acetone for 10 minutes and stained by a sensitive indirect 
immunoperoxidase procedure, using Moab RC38 and anti-endothelial 
MoAb PAL-Ε и at appropriate dilutions and goat anti-mouse IgG 
conjugated to horse-radish-peroxidase (HRP, TAGO Ine , Burhngame, CA, 
USA) as secondary antibody З-3-Di-Amino-Benzidine (DAB) containing 1 
mM imidazole and 0 01% H202 was used as substrate for 10 minutes 7 In 
a double staining experiment, sections of a lung carcinoma metastasis in 
the brain DAB stained with RC38 (brown precipitate) were washed 3 times 
with 0 1 M Glycine-HCL pH 3 0 to remove bound primary antibody and 
conjugate, and then stained with anti-endothelial MoAb PAL-Ε using 
4-Chloro-l-Naphthol as substrate (blue-gray precipitate) Sections were 
counterstained with hematoxylin The sections were examined by two 
independent observers (ROS and DJR) In the occasional case of 
discrepancy the slides were jointly reevaluated until consensus was 
reached Staining intensity was graded as follows no staining (-), weak 
staining ( + /-), moderate staining ( + ) or intense staining (+ +) 
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Immuno-electron microscopy 
A pre-embedding immunoperoxidase technique described in detail 
elsewhere 7 '5 was used to demonstrate the ultrastructural distribution of the 
staining with MoAb RC38 Briefly, surgical material with a maximum size 
of 4x6x2 mm was promptly fixed for 4 hours in 2% paraformaldehyde in 
Sorensen buffer (pH 7 4) After washing in 2 3 M sucrose solution, the 
tissue was immediately frozen in liquid nitrogen and stored at -196 °C On 
a cryomicrotome (Micron, Heidelberg, Germany) 30 μπι sections were cut 
at -20°C These sections were incubated overnight with the first antibody 
at 4°C After washing, the sections were incubated at RT for 1 5 hours 
with a peroxidase-conjugated rabbit-anti-mouse and/or swine-anti-rabbit 
antibody (Dakopatts/ITK) at appropriate dilutions in PBG Control sections 
were incubated with the second antibodies alone After extensive washing, 
the sections were incubated in a 5 mg/ml DAB solution in PBS, containing 
3 mg/ml ammonium-nickel-sulfate-hexahydrate (FLUKA 09885, Buchs, 
Switzerland) The sections were then developed for 8-10 min in the same 
solution containing 0 01% H202 (30%) The reaction was terminated by 
rinsing with tap water The sections were post-fixed in 1 % Osmium 
tetroxide for 5 mm at RT, dehydrated and embedded in Epon 812 
Ultrathin sections were contrasted for 1 min with uranyl-acetate 3% and 
examined and photographed with a JEOL 1200 EX/II electron microscope 
(Tokyo, Japan) at 40 KV 
Characterization of RC38 antigen 
Sequential immunoprecipitation with MoAb RC38 and MoAb S4, an 
antibody known to recognize human aminopeptidase A 2 2 2 3 was performed 
as follows SK-RC-1 cells were metabohcally labelled overnight with 3H-
glucosamine, washed, and lysed as described 23 Cell lysates were 
incubated with RC38 or S4 for two hours and incubated with Sepharose-
CL-4B protein A beads After one hour, the beads were washed, and the 
immunoprecipitates were separated by Polyacrylamide gelelectrophoration 
(PAAGE) Autoradiography was performed using Kodak diagnostic film 
Films were developed in a Kodak RP X-OMAT processor (Eastman 
92 
Aminopeptidase-A in activated pericytes 
Kodak, Rochester, NY). Lysates depleted by RC38 or S4 were treated with 
the same MoAb as described above, to assure complete depletion of the 
lysate of their respective antigens. These immunoprecipitates were also 
investigated by PA AGE. Thereafter, RC38-treated lysates were incubated 
with MoAb S4 and vice versa. The remainder of the procedure was as 
described above. 
Results 
Tissue distribution of MoAb RC38 
The distribution of the antigen recognized by MoAb RC38 was studied 
using immunohistochemistry on frozen tissue sections. A variable but often 
intense staining of capillaries and small venules with MoAb RC38 was 
observed in the stroma of most neoplasms (fig. lc,f). In benign lesions of 
the breast, microvascular RC38 staining was strong in proliferative 
mastopathy but weaker in other lesions (table 2). 
In vasoformative tumors profound staining of stromal capillaries was seen. 
The multilayered cell layer lining the vascular spaces of a pyogenic 
granuloma and some spindle cell areas in an angiosarcoma were also 
positive (results not shown). 
In chronically inflamed synovias and in the superficial parts of granulation 
tissue in decubitus lesions, vascular staining with Moab RC38 was also 
observed (fig. la,d). In the deeper fibrous areas of granulation tissues and 
in adjacent normal skin, RC38 staining was focally weak or absent. 
Capillaries and small venules in normal tissues showed only focal and weak 
positivity in pancreas, lymphoid tissues and intestinal mucosa. In the other 
normal tissues no microvascular staining with MoAb RC38 was observed. 
Smooth muscle cells in the walls of arterioles, arteries and larger veins 
were negative in all tissues (fig. lb,e). 
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FlG. 1. Immunoperoxidase staining with anti-endothelium MoAb PAL-Ε (a,b,c) and with 
anti-ΑΡΑ MoAb RC 38 (d,e,f) of adjacent frozen tissue sections of surgically removed 
granulation tissue (a,d) and serial sections of normal colon (b,e) and colon carcinoma (c,f). 
MoAb RC 38 stains microvessels in the granulation tissue and tumor stroma, while in 
normal colon mucosa and submucosa microvessels are staining with MoAb PAL-E 
(indicated by arrows), but not with MoAb RC 38. 
TABLE 2. STAINING OF VASCULAR STRUCTURES WITH MOAB RC38 IN NORMAL TISSUES 
AND BENIGN AND MALIGNANT TUMORS OF BREAST AND COLON. 
Tissue Number Microvascular staining 
Breast normal mammary gland 3 
non-proliferative mastopathy 4 
proliferative mastopathy 4 
carcinoma 8 
Colon normal mucosa 4 
adenoma 4 
carcinoma 8 
- or 
- or 
+ + 
+ + 
- or 
+/-
+ + 
+/-• 
+/-
+/-
or + + 
+ /- = sporadic weak staining 
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The epithelium of the proximal tubulus and glomerulus of the normal 
kidney showed marked staining, while reactivity was also found in the 
luminal epithelial brush border of the small intestine and colon, the 
placental trophoblast, in the red pulp of spleen and in periportal sinusoidal 
liver cells (a pattern suggestive for staining of Kupffer or Ito cells) (results 
not shown). 
In the RC38 staining microvessels in tumors and granulation tissue 
occasionally unstained luminal cells were seen, suggesting that non­
endothelial cells were recognized by the antibody (fig. If). To investigate 
which cells were recognized, a double-staining experiment was performed 
in sections of a lung carcinoma metastasis to the brain with MoAb RC38 
and with MoAb PAL-Ε, a general endothelial marker. The complementary 
staining pattern for PAL-Ε (luminal cells) and RC38 (abluminal cells) 
suggested staining of endothelial cells and pericytes, respectively (results 
not shown). 
Immuno-electron microscopy 
Distribution of the RC38 antigen at the ultrastructural level was studied 
using a pre-embedding immunoperoxidase staining of thick cryomicrotome 
sections of a glioblastoma, a neuroblastoma, 3 colon carcinomas, normal 
kidney and prostate. 
In all tumors a marked staining of pericyte cell membranes and pericyte 
processes was observed (fig. 2). In the normal kidney, staining with RC38 
was confined to the brush border of the epithelium of renal proximal tubuli 
and glomeruli. Pericytes and their processes, observed in the wall of 
capillaries in normal kidney and prostate, did not stain (results not shown). 
In none of the examined tissues endothelial staining was observed. 
Cultured cells 
No staining of endothelial cells, fibroblasts, keratinocytes and melanocytes 
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in primary human foreskin cultures, or of cultured human brain pericytes 
and endothelial cells from umbilical vein was found. A weak staining was 
seen in SK-RC-1 renal carcinoma cells (results not shown). 
Biochemical characterization ofRC38 antigen 
The RC38 antigen showed a very similar normal tissue distribution as the 
antigen recognized by MoAb S4 '6. We therefore investigated whether 
RC38 antigen might be identical to S4 antigen. Radioimmunoprecipitation 
of SK-RC-1 cells with RC38 revealed the specific precipitation of a 
glycoprotein with a molecular weight of 160 kD (gpl60), identical to the 
antigen recognized by MoAb S4. However, where S4 precipitates revealed 
multiple gpl60 species, probably due to different glycosylation patterns 22, 
the RC38 precipitates showed only one discrete gpl60. The molecule 
recognized by MoAb S4 has recently been identified as aminopeptidase-A 
23
. Sequential immunoprecipitation of gpl60-positive cell lysates revealed 
that RC38 was unable to deplete any gpl60 from S4-depleted material. In 
F I G . 2. Electronmicroscopy of 
immunoperoxidase staining with 
anti-ΑΡΑ MoAb RC 38 in an area 
with glomeruloid microvascular 
proliferation in a surgically 
removed glioblastoma multiforme. 
Note staining of pericytes (P) and 
their processes. Endothelial cells 
(E) are not stained. The asterisk 
indicates lumen; bar = 3 micro­
meter. 
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the reverse experiment, S4 precipitated gpl60 material, with a clear defect 
of the RC38-related gpl60, indicating that RC38 recognizes a subset of the 
S4-related gpl60 
Discussion 
Pericytes are found in varying numbers in all organs 26, but their function 
is poorly understood Like vascular smooth muscle cells they contain all 
necessary elements for contraction, suggesting a role in the regulation of 
bloodflow in the microvasculature 2 26 
Recently these cells have received much attention as to their presumed role 
in the process of angiogenesis Early reports suggested a function in 
mechanical support and basement membrane formation in newly formed 
vessels 26, but more recently pericytes have been proposed to act as 
controllers of endothelial proliferation in resting tissues which, during 
angiogenesis, appear only in the end stage of angiogenesis l4272S Indeed, 
in vitro, pericytes are able of inhibiting endothelial proliferation in co-
cultures 4S However, morphological studies of angiogenesis in vivo 
demonstrate pericytes in the earliest stages of vascular sprout formation and 
support an active role of these cells in all the stages of neovascularization 7 
10 
In tumors and other conditions with neovascularization, pericytes differ 
morphologically from their normal tissue counterparts They are more 
plump, show signs of amoeboid movement, are mitotically active and have 
an increased number of cell organelles " '3 Recently, we reported that 
such "activated" pericytes have enhanced expression of a 
glycosaminoglycan known as the High Molecular Weight Melanoma 
Associated Antigen (HMW-MAA) 7 From this study we concluded that 
activated pericytes have an altered phenotype and are present in increased 
numbers in the microvasculature of tissues with neovascularization In 
addition, activated pericytes were recently shown to express the receptor 
for Epidermal Growth Factor in granulation tissue 29 
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Here we report on the microvascular distribution of human aminopeptidase 
А (APA, glutamyl transpeptidase, E.C. 3.4.11.7) as recognized by MoAb 
RC38 16. Similarly to HMW-MAA, we noted strong staining for RC38-
related APA of microvessels in tumors and granulation tissue. Much 
weaker or absent microvascular RC38 staining was found in normal 
tissues. By immuno-electonmicroscopy, the cells staining in these vessels 
were identified as activated pericytes. These observations suggest a 
quantitative upregulation of RC38-related APA in activated pericytes. 
Biochemical comparison of the antigens recognized by MoAb RC38 and 
MoAb S4, the latter identifying human APA 2 2 · 2 3 , revealed that MoAb 
RC38 recognized a subspecies of aminopeptidase-A. Sequential 
radioimmunoprecipitations with MoAb S4 and MoAb RC38 showed that 
MoAb RC38-depleted ΑΡΑ-containing lysates still contained S4-
precipitable material, but not vice versa. As RC38 recognizes a peptide 
sequence 16, and not a carbohydrate moiety, it is likely that the MoAb 
RC38 epitope is masked in the APA that is still precipitable by MoAb S4. 
Early distribution studies on APA in animal and human tissues by enzyme 
histochemistry demonstrated active APA in brush border epithelia in the 
kidney and small intestine and in the vasculature of all organs 1 7 J 9. The 
latter was interpreted as endothelial reactivity 17. Recently however, APA 
in the rat brain was demonstrated in pericytes by immunohistochemical 
staining 20, suggesting that also in other organs pericytes may be the source 
of microvascular APA. MoAb S4, shown to recognize human APA 2 \ does 
stain microvessels in normal tissues (Personal communication Dr. C.L. 
Finstad). It is therefore surprising that MoAb RC38 shows only a weak or 
absent microvascular staining in normal tissues. This suggests, like our 
biochemical findings, that RC38 recognizes a separate species of APA 
(probably underglycosylated) that has enhanced expression in activated 
pericytes and therefore may have a special function in these cells, possibly 
related to angiogenesis. 
APA is not the first ectoenzyme demonstrated on pericytes. Previously, 
gamma-glutamyl transpeptidase and aminopeptidase M were localized in 
brain pericytes 3 0 · 3 1 . As these enzymes may regulate or neutralize 
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neurotransmitters and other active oligopeptides, their expression by 
cerebral pericytes was considered as a sign of involvement of these cells in 
the blood-brain barrier function of brain vessels Ж 3 1 . 
Aminopeptidase A has not previously been implied to play a role in 
pericyte activation or angiogenesis. The enzyme acts on peptides with an 
N-terminal acidic amino acid and hydrolyzes therefore selectively glutamyl 
and aspartyl residues 20·23·32. An important substrate of APA is angiotensin 
II, which is metabolized into angiotensin III. These are both potent 
vasoactive peptides with systemic and local effects on vascular tone 20. 
Interestingly, angiotensin II can also stimulate angiogenesis in the rabbit 
cornea and chorioallantois membrane (CAM) angiogenesis assays 3 2 3 5. 
Recently, a novel receptor for angiotensin II was demonstrated in the CAM 
34
 and this receptor is probably located on the pericytes 36. We suggest that 
APA is involved in the degradation by pericytes of angiotensin II and other 
important regulatory oligopeptides 23 involved in tissue regeneration and 
angiogenesis. The numerous activated pericytes in microvessels in 
angiogenesis 7 ,e are strategically localized to act, by their expression of 
APA, as regulators of the activity of such factors. 
Vascular smooth muscle cells were not stained with Moab RC38. This 
observation is interesting, as pericytes and smooth muscle cells have many 
common features and are regarded as closely related cell types АЛ. 
Membrane determinants distinguishing these cell types could be useful in 
histopathology or to help to identify functional differences 2'3,31. 
In conclusion, the special form of APA that is recognized by MoAb RC38 
in activated pericytes may provide these cells with a regulatory ectoenzyme 
involved in the process of angiogenesis. Our findings give further evidence 
for an altered phenotype of activated pericytes and identify MoAb RC38 as 
another marker for these cells in conditions with neovascularization. 
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Summary 
Glioblastoma multiforme (GBM) frequently shows glomeruloid 
microvascular proliferation (MVP), characterized by coiled masses of 
capillaries with multilayered proliferation of cells in the vessel wall This 
architecture suggests a relative lack of directional invasion of microvascular 
cells into the surrounding glial (tumor) tissue For such invasive 
angiogenesis, interactions between intégrais and the extracellular matrix 
(ECM) are essential In the present immunohistochemical study of GBMs, 
the expression of (subunits of) ECM-binding integrins (αΐ-аб, αν, ßl, ß3-
ß5, avß3, avß5) is systematically assessed in delicate versus glomeruloid 
microvessels, and compared with the microvascular expression in normal 
brain and in intracerebral metastatic carcinomas Additionally, the 
distribution of the complementary ECM-components collagen I and IV, 
laminin, fibronectin, and vitronectin is assessed in these tissues Compared 
to normal brain tissue, both delicate and glomeruloid microvessels in 
GBMs showed an increased expression of αϊ, α4, α5, αν, avß3, avß5, of 
which especially avß3 has been implicated in invasive angiogenesis In the 
intervascular, normal and neoplastic glial tissue most complementary ECM-
components were absent, while in intracerebral metastatic carcinomas a 
variable amount of these components was present We conclude that 
inadequate interactions between microvascular adhesion molecules and the 
surrounding glial ECM may contribute to aberrant angiogenesis in GBMs, 
but that the complexity of this process precludes simple conclusions 
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Introduction 
Angiogenesis is defined as the outgrowth of new vessels from the 
preexisting vasculature. Folkman hypothesized that solid tumors are 
dependent on angiogenesis for sustained growth and that anti-angiogenic 
treatment is a potential therapy ' ,2. The most frequent and most malignant 
human glial neoplasm, glioblastoma multiforme (GBM), frequently shows a 
remarkably florid or glomeruloid microvascular proliferation (MVP) 3 \ 
characterized by the formation of coiled masses of capillaries with 
multilayered proliferation of swollen endothelial cells (ECs) and pericytes 
in the vessel wall 5"8. Since this MVP gives the impression of a highly 
vascularized tumor, GBM has become an especially strong candidate for 
anti-angiogenic treatment 9 " . Expectations for success were strengthened 
by animal studies in which the growth of gliomas could indeed be inhibited 
by anti-angiogenic therapy 1 2 1 5. Further elucidation of the pathogenesis and 
biological significance of MVP in human GBM is essential for developing 
a rational treatment directed against neovascularization in these tumors. 
The formation of delicate microvascular sprouts during classic, invasive 
angiogenesis is dependent on multiple, temporally and spatially coordinated 
steps, including production and release of angiogenic factors, directional 
migration and proliferation of microvascular cells, proteolytic degradation 
of extracellular matrix (ECM) barriers, and the composition of new vessels 
16 20
. Experimental data show that directional invasion of ECs is controlled 
by the ability of these cells to exert mechanical forces on the surrounding 
ECM 21-22. Most of the identified endothelial adhesion molecules for ECM 
components are members of a family of αβ-heterodimeric cell membrane 
receptors called integrins 2 3 2 4. The expression and activation of these 
adhesion molecules is modulated by cytokines and angiogenic factors 1 6 1 7. 
Glomeruloid MVP in GBMs is attributed to the increased production and 
release of angiogenic factors, especially of Vascular Endothelial Growth 
Factor / Vascular Permeability Factor (VEGF/VPF) ^ 2 6 . The VEGF 
expression appears to be upregulated by hypoxia 27. This observation may 
account for the well known propensity for glomeruloid MVP in GBMs to 
occur adjacent to necrotic foci. The glomeruloid architecture suggests a 
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relative lack of directional migration of proliferating microvascular cells 
into the surrounding glial (tumor) tissue 28,29. A recent study indicates that, 
while angiogenic factors stimulate EC proliferation, the pericapillary ECM 
is decisive for capillary morphogenesis 30. We hypothesize that glomeruloid 
MVP in GBMs represents unbalanced or "frustrated" angiogenesis, and that 
inadequate interactions between microvascular cells and the glial ECM 
contribute to the peculiar architecture of this MVP. In the present study, 
the expression of (subunits of) ECM-binding integrins (αΐ-аб, αν, ßl, ß3-
ß5, avß3, avß5) and of complementary ECM-components (collagen I and 
IV, laminin, fibronectin, vitronectin) in/around florid MVP is compared 
with the expression in/around delicate microvessels in GBMs, normal 
brain, and intracerebral metastatic carcinomas. 
Materials and Methods 
Tissues 
Fragments of the following surgical tissues were snap frozen: supratentorial 
GBMs (n = 18); histologically normal brain tissue (n = 4); intracerebral 
metastatic carcinomas (n = 7; primary tumors: adenocarcinoma of 
unknown origin, η = 3; squamous cell carcinoma of the lung, η = 2; 
ductal carcinoma of the breast, η = 1; adenocarcinoma of the kidney, η = 
1). Florid MVP was present in cryostat sections of 11 out of 18 GBMs. 
The normal brain tissue obtained by surgery was removed for technical 
reasons during operation for a low grade glioma (n = 3) and a vascular 
malformation (n = 1), only after careful microscopic evaluation this 
surgical material was considered to be histologically normal. Additional 
fragments of snap frozen, histologically normal brain tissue were obtained 
by rapid autopsy on patients who had died of non-cerebral disorders (n = 
5; post mortem delay less than 6 hours). Histological typing of the glial 
tumors was performed on hematoxylin-eosin stained sections of formalin-
fixed, paraffin-embedded tissue according to the revised WHO-
classification 31. 
106 
Microvascular integrals in glioblastomas 
Antibodies 
The following, well characterized monoclonal antibodies (MoAbs) and 
polyclonal antibodies (PoAbs) were used for detection of (subunits of) 
integrins and ECM components: MoAb TS2/7 for αϊ (source T-cell 
Science, Cambridge MA, USA; reference 32; dilution: ascites (asc) 
1:1000), MoAb Gil4 for a2 (Dr. Santoso, Giessen, Germany; 33; 
supernatant of hybridoma culture (sup) 1:10), MoAb J143 for a3 (Dr. 
Danen, Nijmegen, The Netherlands; 34; sup. 1:10), MoAb HP2/1 for a4 
(Immunotech S.A., Marseille, France; 35; asc. 1:1000), MoAb SAM-1 for 
a5 (Dr. Figdor, Nijmegen, The Netherlands; 36; asc. 1:1000), MoAb 
MT78 for a6 (Dr. Klein, Würzburg, Germany; 37; 1 Mg/ml), MoAb AMF-
7 for αν (Dr. Figdor; 38; sup. 1:10), MoAb 4b4 for ßl (Coulter 
Immunology, Hialeah FL, USA; 39; 5 Mg/ml), MoAb C17 for ß3 (Dr. 
Sonnenberg, Amsterdam, The Netherlands; m\ asc. 1:1000), MoAb 3E1 
for ß4 (Telios Pharmaceuticals Inc., San Diego CA, USA; 4I; asc. 1:4000), 
MoAb IA9 for ß5 (Dr. Hemler, Boston MA, USA; "2; asc. 1:1000), MoAb 
LM609 for avß3 (Dr. Cheresh, La Jolla CA, USA; 43; asc. 1:1000), 
MoAb P1F6 for avß5 (Gibco, Gaithersburg MD, USA; **; asc. 1:1000), 
MoAb for collagen I (Monosan/Sanbio b.v., Uden, The Netherlands; 
1:20), PoAb for collagen IV (Euro-Diagnostics/Organon, Boxtel, The 
Netherlands; 1:800), PoAb for laminin (Euro-Diagnostics/Organon; 1:400), 
MoAb for fibronectin (Telios Pharmaceuticals, Inc.; 1:200), and MoAb for 
vitronectin (Telios Pharmaceuticals, Inc.; 1:320). Additionally, the MoAb 
anti-High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) 
was used as a marker for "activated" pericytes in the microvasculature of 
GBMs6. Optimal working dilutions were determined previously 6 · 4 5 4 6 . 
Immunohistochemistry 
Cryostat sections of all cases were stained with MoAbs against the 
(subunits of) integrins αΐ-аб, αν, ßl, ß4, avß3, avß5, and with MoAbs 
and PoAbs against complementary ECM-components present in interstitial 
connective tissue (collagen I, fibronectin, vitronectin) and basement 
membranes (collagen IV, laminin). Additionally, cryostat sections of 10 
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GBMs were stained with MoAbs against the integrin chains ß3 and ß5 and 
against HMW-MAA. Serial 4 μιτι-sections of snap frozen tissue were air-
dried, fixed in acetone for 10 minutes at room temperature (RT) and then 
incubated with the Abs at RT for 60 minutes. Abs were diluted in 
phosphate-buffered saline (PBS) containing 1 % bovine serum albumin 
(BSA). After rinsing the sections three times with PBS, the primary Abs 
were detected by incubation at RT with a (horse radish) peroxidase-
conjugated rabbit-anti-mouse immunoglobulin (DAKO, Copenhagen, 
Denmark), followed by three wash steps with PBS and incubation with 
DAB (3,3'-Diaminobenzidine-tetrahydrochloride, Sigma Diagnostics, St. 
Louis, Mo., USA) as chromogen. Then the sections were rinsed in tap 
water, treated with CuS04 and counterstained with hematoxylin-Mayer 
(Merck, Darmstadt, Germany). Finally, the sections were again rinsed in 
tap water, dehydrated with ethanol, and mounted with Permount (Boom 
b.v., Meppel, The Netherlands). Negative controls consisted of incubations 
replacing the primary Ab with PBS-BSA. 
Quantification of results 
In each case of normal brain and GBM, the number and appearance of 
microvessels was evaluated in the collagen IV staining. Subsequently, in 
the sections stained for integrine the immunoreactivity of delicate 
microvessels and of florid MVP was semi-quantitatively assessed according 
to the extent (none = no staining; some = less than 50% of the vessels 
positive; most = 50% or more of the vessels positive) and the intensity of 
the staining (weak or marked). Half of the slides were independently 
evaluated by a second observer (EHJD); no significant differences were 
found between these evaluations. 
Results 
Integrins 
The results of the immunohistochemical stainings for (subunits of) integrins 
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in the microvasculature of normal brain and GBMs are summarized in fig. 
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FIG. 1. Percentage of cases with microvascular staining for (subunits of) integrins. 1 = 
cases of normal brain with staining of capillaries; 2 = cases of GBM with staining of 
delicate capillaries; 3 = cases of GBM with staining of florid MVP. Cases showing staining 
of 50 % or more of the microvessels are represented by black bars, cases showing staining 
of less than 50% of the microvessels are represented by grey bars. For reasons of clarity, 
in this figure the information about the intensity of the stainings is omitted. 
Normal brain 
The microvessels were strongly αϊ- and ßl-positive (fig. 2a) and variably 
positive for a2, аЗ, а5, аб, αν, ß4, and avß5. The exact cellular 
localization (ECs or pericytes) of the integrins in the microvascular wall 
could not be determined by light microscopy. Microvascular expression of 
a4 and avß3 was absent in normal brain (fig. 2b). The subpial and 
perivascular glial limiting membrane often showed a linear staining for α ϊ , 
аЗ, аб, ßl , and ß4 (fig. 2a). Staining for integrin chains was generally 
absent in the neuropil, in a minority of cases a local and mostly only weak 
staining was present for a5, av, and ßl. 
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FIG. 2. Examples of ïmmunohistochemical integnn stamings on frozen sections of normal 
brain (a,b), GBM (c-g), and intracerebral metastasis of squamous cell carcinoma of the 
lung (ij) and of HMW-MAA staining of GBM (h); a ßl, b avß3, с: α ϊ , d α4; e ßl , f. 
α3, g а ВЗ, h HMW-MAA, i ß4, j . cxvß3 a-j original magnification x200, 
counterstaining with hematoxylin c&d, e&f, g&h are serial sections Note the staining of 
tumor microvessels for «4 (d) and avß3 (gj) and the absence of staining for avß3 in 
normal brain (b), the <*3 staining of the glial limiting membrane around unstained 
glomeruloid MVP (f), the staining of abluminal cells in the vessel wall (consistent with 
pencytes/vascular smooth muscle cells) in both HMW-MAA and а ВЗ (g,h). Arrows in 
a,e,f indicate perivascular glial limiting membrane, arrows in j indicate а ВЗ-positive 
microvessels 
GBM. 
The microvessels m GBMs (including those showing florid MVP) were 
strongly αϊ- and ßl-positive (fig. 2c,e) and variably a6- and ß4-positive. 
In contrast to normal brain, some GBMs showed variable expression of a4 
and avß3 in part of the microvessels, especially in florid MVP (fig. 2d,g). 
The distribution of the microvascular avß3 staining in this MVP and 
comparison with the anti-HMW-MAA staining suggested that not only 
ECs, but also pericytes/vascular smooth muscle cells were positive (fig. 
2g,h) The number of α2-, α5-, αν-, and avß5-positive microvessels also 
was increased in GBMs, but since in these stainings the glial tumor tissue 
was variably positive as well, unequivocal assessment of the microvascular 
staining was somewhat difficult in delicate microvessels. Such vessels were 
considered to be positive when no negative microvascular profiles could be 
traced The ß3- and ß5-staining showed essentially the same distribution 
but a weaker intensity as the avß3- and avß5-staining, respectively. 
Additionally, in the ß3-staining intravascular platelet thrombi were strongly 
positive. The ß4 staining was reduced in florid MVP. The glial limiting 
membrane in GBMs showed a similar staining pattern as in normal brain, 
even around florid MVP a variable linear staining for α ϊ , аЗ, аб, ßl, and 
ß4 was often present (fig. 2e,f) The intervascular glial tumor tissue 
showed a variable but mostly weak expression of а2, аЗ, а5, аб, αν, ßl , 
ß4, ß5, and avß5, and occasionally of α4, ß3, and avß3. 
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Intracerebral metastatic carcinomas 
The integrin expression on tumor cells and in tumor stroma was highly 
variable within and between intracerebral metastatic carcinomas. Some 
integrin chains (αϊ, α6, ß4) were especially found at the basement 
membrane around clusters of carcinoma cells (fig. 2i) and/or blood vessels, 
while others were more diffusely expressed by the carcinoma and stromal 
cells (а2, аЗ, α5, αν, ßl , avß5). In the latter stainings, the assessment of 
the microvascular integrin staining was difficult in a background of positive 
connective tissue. While in the a4-, avß3-, and avß5-staining most 
microvessels were negative, in some cases part of the microvessels showed 
a weak but unequivocal staining (fig. 2j). 
ECM-components 
Normal brain 
In normal brain, the intervascular glial tissue was negative, while the 
microvessels and glial limiting membranes were strongly positive for 
collagen I, collagen IV, and laminin, variably positive for fibronectin, and 
only weakly positive or negative for vitronectin. 
GBM 
In GBMs the microvessels (including florid MVP) and the glial limiting 
membranes showed the same staining pattern as in normal brain for 
collagen I, collagen IV, and laminin, while the intensity of staining for 
fibronectin and vitronectin was increased in especially florid MVP (fig. 
3a). The tumor tissue surrounding both delicate microvessels and florid 
MVP was generally negative. In some GBMs a local vitronectin staining of 
variable intensity was found in the intervascular tissue, this staining was 
not related to florid MVP. Furthermore, in several GBMs granules and 
spurs of the investigated ECM-components were locally present in between 
the glioma cells. Part of these spurs could be traced to the microvascular 
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wall and/or the glial limiting membrane. 
Intracerebral metastatic carcinomas 
Intracerebral metastatic carcinomas contained a variable amount of 
vascularized connective tissue in between the nests of tumor cells. This 
connective tissue was strongly positive for collagen I and fibronectin, and 
variably positive for collagen IV, laminin, and vitronectin (fig. 3b). In the 
collagen IV and laminin staining a strong, linear positivity was present at 
the basement membrane around blood vessels and around nests of 
carcinoma cells. 
FIG. 3. Example of staining for the ECM-component vitronectin in GBM (a) and 
intracerebral metastatic carcinoma of the breast (b); original magnification x200, 
counterstaining with hematoxylin. Note that the vitronectin staining in the intervascular glial 
(tumor) tissue is sparse, while this staining is extensively present between (nests of) 
carcinoma cells. 
Discussion 
Compared to microvessels in normal brain, we found in GBMs an 
increased expression of particular integrins (esp. al, α4, α5, αν, avß3, 
avß5) in both delicate and glomeruloid microvessels and a reduced Ы 
staining of florid MVP. As reported previously (for review see 4 7), 
collagen I and IV, laminin, and fibronectin in GBMs were essentially 
confined to the walls of both delicate microvessels and florid MVP. 
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Additionally, in GBMs we found a local and variable vitronectin staining of 
the glial tissue; this staining was not clearly related to areas with florid 
MVP. Within intracerebral metastatic carcinomas, on the other hand, the 
microvessels were incorporated in a variable amount of connective tissue 
containing fibronectin, collagens, laminin, and vitronectin. 
Our data extend on those of previous studies that assessed the expression of 
ECM-binding integrins in GBMs, only some of these studies systematically 
assessed the integrin expression in florid MVP versus delicate 
microvessels. Compared to normal brain, Paulus et al. described a reduced 
ß4 staining of ECs in malignant gliomas and an increased a4 expression in 
especially abnormal vascular proliferations "8. Other studies (also) reported 
on a diminished microvascular ß4 expression in astrocytic tumors 49 and an 
increased microvascular expression of a2ßl and a4ßl in GBMs compared 
to normal brain 50. Vitólo et al. described a difference in microvascular 
integrin expression in different types of "endothelial cell proliferations" 5I. 
Microvascular expression of avß3 in GBMs has been reported by several 
authors 5 0 · 5 2 5 3 . One study suggests that both ECs and "adjacent 
mesenchymal cells" (consistent with pericytes) express this integrin 5 \ this 
suggestion is corroborated by our findings in serial sections stained for 
avß3 and HMW-MAA, respectively. The microvascular avß3 expression 
reported in histologically normal brain 52 may (partly) be explained by 
diffusable, tumor-related cytokines 54. 
The complex cell-matrix interactions necessary for invasive angiogenesis 
are slowly revealed. The exact role of microvascular, ECM-binding 
integrins and other adhesion molecules during this process is still largely 
obscure l61855. Recently, two angiogenic pathways were defined on the 
basis of dependency on vascular expression of avß3 and avß5, respectively 
56
. While the latter is considered as a vitronectin receptor, avß3 is a 
promiscuous adhesion molecule, capable of recognizing a wide variety of 
ECM proteins 24·54. Generally, in granulation tissue and in tumor stroma an 
early scaffold for migration of microvascular and other cells is formed by a 
provisional matrix composed of fibrin, fibronectin, and vitronectin 576°. 
Subsequently, microvascular cells produce matrix components like collagen 
I and IV and laminin that are incorporated in the provisional ECM 57·61-64. 
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Finally, fibroblasts may stabilize newly formed vessels by enhancing the 
production and perivascular deposition of ECM 65. 
In our study at least part of the glomeruloid MVP in GBMs showed 
expression of integrins relevant for invasive angiogenesis, but the 
surrounding glial compartment only locally contained the investigated 
complementary ECM ligands (esp. vitronectin). The presence of 
glomeruloid MVP around rather than within intracerebral metastatic 
carcinomas ^68 supports the notion that there may be something about the 
brain's microenvironment that inhibits the formation of vascular sprouts. 
Interestingly, the ECM of the adult brain shows a striking similarity to the 
ECM of cartilage 69, a tissue that is notoriously resistant to ingrowth of 
blood vessels. In the developing brain, the transient expressioa by glial 
cells of ECM components such as laminin and fibronectin may help to 
guide not only neurons/neurites, but also microvascular cells to their final 
destination 70·71. Cells that do show diffuse infiltration in the adult glial 
compartment (e.g. glioma and lymphoma cells) apparently use other 
molecules like gangliosides and adhesion molecules of the CD44 family, 
especially since the glial ECM is rich in hyaluronic acid, a potent ligand of 
CD44 6 9 · 7 2 7 5 . Some areas of GBMs do show classic angiogenesis with the 
formation of delicate microvascular sprouts 76. Such an invasive angiogenic 
reaction could be facilitated by an altered expression by tumor and/or 
vascular cells of the presently investigated ECM components (e.g. 
vitronectin), or of alternative ECM ligands of integrins and other adhesion 
molecules (e.g. fibrin, tenascin, osteopontin, thrombospondin77"81). 
Since avß3 plays a critical role in the angiogenic process, the expression of 
this integrin in GBMs is of particular interest. While the microvascular 
expression in normal tissues is usually minimal, this expression is 
transiently upregulated during angiogenesis and dissipates once blood 
vessels in granulation tissue mature 55·60·82. Using the same MoAb for 
avß3 as described by others ^ 6 0 · 8 2 , in our study only part of the delicate 
and glomeruloid microvessels in GBMs were o;vß3-positive. During 
granulation tissue formation in porcine wounds, invasive capillary sprouts 
seemed to be derived from hypertrophied vessels immediately adjacent to 
the wound. Both the hypertrophied vessels and the invasive capillary 
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sprouts expressed avß3 ω By analogy with the hypertrophied vessels in 
this wound healing model, avß3-positive glomeruloid MVP in GBMs may 
function as a starting point for invasive angiogenesis when the right 
perivascular (matrix) conditions are available 
In conclusion, in our study at least part of the glomeruloid MVP in GBMs 
expresses integrine relevant for invasive angiogenesis, but in large areas of 
the surrounding brain parenchyma a scaffold of the investigated 
complementary ECM ligands is lacking As a consequence, glomeruloid 
MVP could represent angiogenesis that is incomplete or even "frustrated", 
and the interdiction of this MVP by anti-angiogenic treatment may have 
limited therapeutic effect However, the angiogenic process is too complex 
to draw simple conclusions The distribution of the complete spectrum of 
integrin ligands in and around glomeruloid MVP in GBMs remains to be 
established, and microvascular adhesion molecules other than mtegnns are 
likely to play a role in this process 1655 Furthermore, on the basis of our 
study, a contribution of other factors (e g production of unusual levels or 
combinations of angiogenic factors, lack of rigidity of the perivascular 
ECM 83, untimely expression or inadequate activation of microvascular 
mtegnns and proteases M) to the development of glomeruloid MVP cannot 
be excluded Further elucidation of the pathogenesis of this peculiar 
angiogenic reaction will lead to a better insight into the different steps of, 
and may provide additional targets for interference with (tumor) 
angiogenesis 
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Chapter 8 
Summary 
Angiogenesis is the outgrowth of new blood vessels from the préexistent 
vasculature. In 1971, Folkman hypothesized that solid tumors are 
dependent on angiogenesis for sustained growth and that anti-angiogenic 
treatment is a potential antineoplastic therapy. Because glioblastoma 
multiforme (GBM) frequently shows florid microvascular proliferation 
(MVP), this tumor has been considered since then as a suitable candidate 
for such treatment that attempts to eradicate or control a neoplasm by 
interfering with its blood supply. Indeed, in animal models the growth of 
glioma xenografts can be inhibited by targeting the angiogenic process. 
However, unlike many glioma xenografts, human infiltrating gliomas such 
as GBMs have a diffuse infiltrative growth pattern, and préexistent vessels 
may suffice to provide many tumor cells with much of their blood supply, 
particularly in the critical peripheral infiltrative margins. Thus, while 
attractive in concept, anti-angiogenic therapy of GBM must address the 
anatomic vascular realities of this neoplasm. Even if anti-angiogenic 
therapy ultimately has a role in infiltrative neoplasms, there are a host of 
other intracranial neoplasms whose discrete architecture might make them 
attractive candidates for anti-angiogenic therapy. This review summarizes 
the angiogenic process in GBM and suggests other types of tumors for 
which the efficacy of anti-angiogenic therapy might be studied. 
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Introduction 
Like normal cells in most human tissues, tumor cells are dependent on the 
vasculature for their supply of oxygen and nutrients and removal of waste 
products. Solid tumors need to increase their vascular supply to meet the 
metabolic demands of a growing population of tumor cells. The outgrowth 
of new blood vessels from the préexistent vasculature, "angiogenesis", 
accomplishes this goal '·2. In several neoplasms, angiogenesis not only 
seems to allow tumor growth, but also to increase the probability of tumor 
cells to enter the circulation and metastasize 3. Given this critical role for 
vessels in the enlargement, and possibly metastatic potential, of solid 
tumors, the angiogenic process is a logical target for new anti-cancer 
therapies 4. 
The most frequent and most malignant human glial neoplasm, glioblastoma 
multiforme (GBM), has become an especially strong candidate for such 
treatment " since it frequently shows a remarkable microvascular 
proliferation (MVP) characterized by multilayered proliferation of swollen 
microvascular cells in the vessel wall 8 ·9 . Expectations for success were 
strengthened by animal studies in which the growth of gliomas could 
indeed be inhibited by anti-angiogenic therapy l0"13. 
The aim of this review is to put the expectations about the value of anti-
angiogenic therapy for human brain tumors into perspective of the 
anatomic realities of the vasculature in brain tumors, especially the high 
grade infiltrating types. Since most studies on angiogenesis in brain tumors 
concentrated on astrocytic neoplasms, the astrocytic tumors will be 
highlighted in this review, but other tumors with perhaps more favorable 
tumor-vasculature relationships are also discussed. 
Tumor angiogenesis 
Angiogenesis is involved in a wide range of biological and pathological 
processes, including embryogenesis, endometrial proliferation, wound 
healing, retinal neovascularization, and solid tumor growth 2 '4. In 1945, 
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Algire et al. suggested that an outstanding characteristic of tumor cells is 
their capacity to elicit continuously the growth of new capillary 
endothelium from the host '5. Folkman in 1971 hypothesized that solid 
tumors are dependent on angiogenesis for sustained growth, and that anti-
angiogenic treatment is a potential therapy for these tumors '16. In tumor 
biopsies, the angiogenic capacity may be reflected by the number of 
microvascular profiles in the area with the highest vessel number 
("angiogenic hot spot") 3. In several tumor types (e.g. breast, prostate, and 
non-small cell lung carcinoma) an increased intratumoral microvessel 
density correlated directly with metastasis and inversely with survival 3. 
Angiogenesis thus not only seems to allow tumor growth, but also to 
increase the probability of malignant tumor cells to enter the circulation 
and metastasize. 
Angiogenesis is a complex process, including multiple coordinated steps, 
such as production and release of angiogenic factors, directional migration 
and proliferation of microvascular cells, proteolytic degradation of 
extracellular matrix (ECM) barriers, and the composition of new vessels 
17
·
18
. Angiogenesis is regulated by multiple stimulatory and inhibitory 
factors that are able to modulate the migration and/or proliferation of 
microvascular cells 4I9. Of the angiogenic factors, Vascular Endothelial 
Growth Factor / Vascular Permeability Factor (VEGF/VPF) and acidic and 
basic Fibroblast Growth Factor (a- and b-FGF) have been studied the most 
intensively. The mitogenic activity of VEGF is described to be restricted to 
endothelial cells (ECs), while FGF is mitogenic for a spectrum of cells, 
including vascular smooth muscle cells (VSMCs) and ECs. The VEGF 
expression appears to be upregulated by hypoxia 20 ·21 . As is discussed 
below, the latter observation is of great interest since it may account for 
the well known propensity for glomeruloid MVP in GBMs to occur 
adjacent to necrotic foci. It also suggests that this MVP might be a late 
event in the tumor's evolution. 
During angiogenesis new blood vessels originate mainly from capillaries 
and small venules 2. By definition, the formation of functional vascular 
sprouts depends on directional migration of microvascular cells in the 
surrounding tissue. The mechanisms for migration of these cells are 
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comparable with those involved in invasion of tumor cells 22. Experimental 
data show that directional endothelial migration is controlled by the ability 
of these cells to exert mechanical forces on the ECM of the surrounding 
tissue 23'24. Most of the identified ECM-receptors on ECs are of the integrin 
type и . Recently, two angiogenic pathways were defined in corneal and 
chorioallantoic membrane models on the basis of dependency on vascular 
expression of the integrins avß3 and avß5, respectively 26. For proteolytic 
degradation of ECM barriers, several classes of enzymes, including matrix 
metalloproteinases, serine proteinases (plasminogen activators), and 
cathepsins have been implicated 27. 
While most studies on the effect of angiogenic factors on microvascular 
cells have focussed on ECs, pericytes are extensively involved in the 
angiogenic process as well 2832. Pericytes can be considered as 
multipotential, microvascular representatives of VSMCs, but their role 
during angiogenesis is largely unknown 33,34. In vitro studies demonstrated 
that pericytes can inhibit proliferation of ECs by a mechanism that requires 
contact or close proximity between the two cell types, the inhibition being 
mediated by Transforming Growth Factor-ßl (TGF-ßl) 35~37. Under 
hypoxic conditions, however, cultured pericytes were shown to produce 
VEGF and thus may promote EC growth in a paracrine way 38. The 
increased α-smooth muscle (a-sm) actin expression in the tumor 
microvasculature 3 0 3 2 suggests a contractile role of these cells 39. In 
cultured human brain pericytes the increased expression of a-sm actin has 
been shown to be mediated by TGF-ßl m. The recent demonstration of the 
ectoenzyme aminopeptidase A on pericytes in the tumor microvasculature 
indicates a role in the metabolism of biologically active oligopeptides 41. 
Neuropathology of brain tumors and angiogenesis 
Brain tumor growth patterns 
The most common primary tumors of the human brain are gliomas, 
including neoplasms displaying astrocytic, oligodendroglial, and ependymal 
differentiation. Gliomas rarely metastasize to distant organs, even when 
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high grade. Astrocytic tumors can be divided into the more circumscribed 
lesions (e.g. pilocytic astrocytomas) and the diffusely infiltrating neoplasms 
such as the common fibrillary astrocytic tumors. The latter include the 
GBM. On the basis of four histopathological criteria (nuclear atypia, 
mitotic activity, MVP, and necrosis) diffuse astrocytic neoplasms can be 
divided arbitrarily into three groups of increasing malignancy: astrocytoma 
(A), anaplastic astrocytoma (AA), and GBM 8·9·42·43. Other tumors that 
generally show diffuse infiltration in the préexistent brain tissue are 
oligodendrogliomas and primary central nervous system lymphomas iM. 
Examples of brain tumors with an expanding rather than infiltrative growth 
pattern are meningiomas (fig. 1), meningeal hemangiopericytomas, medul-
loblastomas, hemangioblastomas, ependymomas, pilocytic astrocytomas, 
and metastatic carcinomas 8. 
Î * 
**-tíSfr* ****** 
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FIG. 1. Schematic representation 
of the differences in growth 
pattern between GBM and 
meningioma. Note the compact, 
expanding growth of meningioma 
(represented by black dots) versus 
the diffuse infiltrative growth of 
GBM cells (represented by 
asterisks). While many GBM cells 
may use préexistent vessels for 
their blood supply, the menin-
gioma is largely dependent on 
ingrowth of blood vessels for its 
growth. This figure is based on 
information of "° and "' (Permis-
sion to use part of fig. 66, p.72 of 
ref "° kindly provided by Springer 
Verlag, Heidelberg). 
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The diffuse infiltrative growth of the fibrillary astrocytic neoplasms is now 
well recognized 8 · 4 5 4 7 . Because of this growth pattern, complete surgical 
resection of such astrocytic tumors is often impossible, and eradicating 
tumor cells by chemotherapy and/or radiotherapy without damaging the 
involved brain parenchyma has been difficult to achieve. The prognosis for 
patients with these tumors thus remains poor; the median survival of 
patients with GBMs is less than 1 year and of patients with AAs less than 3 
years 9. Infiltrating astrocytic tumor cells show extensive spread along 
white matter tracts and blood vessels, with isolated cells throughout much 
of the hyperintense areas on T2-weighted MRI scans 4549. For migration 
along blood vessels, interactions between integrine on tumor cells and 
vascular ECM components such as collagens, laminin, and fibronectin are 
considered to be important 50. Within the glial compartment such ECM 
components are generally lacking 5', and diffuse infiltrative growth may be 
facilitated by other molecules like gangliosides and adhesion molecules of 
the CD44 family, especially since the glial ECM is rich in hyaluronic acid, 
a potent ligand of CD44 M-51iì. A recent study suggested that the 
infiltration of glioma, but not of meningioma, cells in brain tissue is a 
reflection of the strong expression of the standard form of CD44 in glioma 
cells versus the weak expression in meningioma cells 54. 
Brain tumor microvasculature 
Florid MVP with prominent, multilayered proliferation of swollen 
microvascular cells in the vessel wall is a well recognized phenomenon in 
some gliomas 8·9. The most prominent form of this MVP was called 
"glomeruloid" MVP because of the formation of coiled, glomerulus-like 
capillary loops 55 (fig. 2). Glomeruloid MVP can also be present in non-
glial tumors such as extracranial neural and neuroendocrine neoplasms 56, 
but is classically associated with GBMs. In the current histopathological 
grading of diffuse astrocytic neoplasms, florid MVP is an important 
criterion to distinguish high grade from low grade tumors 4 2 ·5 7 . While in 
most glial tumors glomeruloid MVP is a sign of malignant progression, in 
pilocytic astrocytomas this MVP does not carry this prognostic significance 
58
. Microscopically, other brain tumors may show a particular 
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microvascular architecture as well. In oligodendrogliomas the delicate 
capillaries are often arranged in a "chicken wire" pattern. 
Hemangioblastomas and (meningeal) hemangiopericytomas are known for a 
very high number of delicate microvessels, in the latter these vessels can 
be present in a "staghorn" configuration 8. 
Florid MVP has long been considered as proliferation of ECs, as is 
apparent in the common designation "endothelial proliferation". Recent 
immuno-light and immuno-electron microscopic studies, however, have 
demonstrated an extensive contribution of pericytes with cytoplasmic a-sm 
actin staining 3032 (fig. 2). These cells are external to ECs in the 
malformed capillaries. Glomeruloid MVP in GBMs often forms arcs or 
serpiginous patterns that are oriented parallel to necrotic areas or to the 
tumor-brain interface 596°. Because of the presence of florid MVP, it has 
been suggested that GBMs depend more on extensive neovascularization 
for continued growth than is the case for "endothelial-poor" tumors. If so, 
then GBMs are good candidates for anti-angiogenic therapy 5"710. Unlike 
angiogenesis in many other tumors 61 ·62 , the MVP in gliomas is usually not 
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accompanied by desmoplasia with proliferation of myofibroblasts. An 
interesting GBM variant combines a glioma and a spindle-cell component 
historically felt to be mesenchymal, hence the designation "gliosarcoma". 
Abundant vascular proliferation is common in these tumors. Based on a-sm 
actin staining of the sarcomatous component of gliosarcomas, it has been 
suggested that this part can originate from the malignant transformation of 
VSMCs in some of these "combined" neoplasms ". Cytogenetic studies, 
however, indicate that in other gliosarcomas the sarcomatous component is, 
in fact, glial in origin on the basis of identical numerical chromosome 
aberrations and p53 tumor suppressor gene mutations in the gliomatous and 
sarcomatous component M · 6 5 . 
Pathogenesis of brain tumor angiogenesis 
Brain tumor angiogenesis ranges from the formation of an abundant 
delicate capillary network in hemangioblastomas to glomeruloid MVP in 
GBMs. That GBMs are a potent source of angiogenic factors has been 
suggested for many years 5·59. Among these, release of the angiogenic 
growth factor VEGF appears to play a pivotal role ^70 . In situ analysis of 
GBMs showed that the production of VEGF is induced especially in tumor 
cells situated close to necrotic foci 20,68. This finding explains the 
topographical relationship between florid MVP and necrosis described 
above. Florid MVP in apparently unaffected neural tissue surrounding glial 
neoplasms may be explained by a relatively high interstitial pressure within 
the tumor, leading to a flow of interstitial fluid containing angiogenic 
factors to the tumor periphery 59,71. For detailed information about the role 
of angiogenic factors and their receptors in brain tumor angiogenesis, the 
reader is referred to recent reviews ^68 . Since the mitogenic activity of 
VEGF appears to be restricted to ECs, other angiogenic factors must be 
involved in the early and extensive contribution of pericytes to florid MVP 
in GBMs. Potential candidates in brain tumors are FGF and Platelet-
Derived Growth Factor (PDGF) 19·30·66·67. in human healing wounds and 
colorectal adenocarcinomas, pericytes rather than ECs were found to 
express PDGF-receptor 72. The prominent phenotype of MVP in GBMs 
may be the result of production of unusual levels or combinations of 
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angiogenic factors in these tumors, leading to unbalanced angiogenesis. 
As seen in light microscopic and electron microscopic sections, the 
architecture of glomeruloid MVP suggests that this proliferation of 
microvascular cells is combined with a relative lack of directional 
migration into the glial (tumor) tissue. The result is the formation of coiled 
masses of capillaries instead of delicate vascular sprouts as seen in classic 
neovascularization 73,74 (fig. 3). 
F I G . 3. Schematic representation of two forms of tumor angiogenesis: a. classic 
angiogenesis with an increased number of delicate microvessels as a result of a balance 
between proliferation of microvascular cells and migration in the direction of the 
hypoxic/necrotic area; b. glomeruloid MVP as a result of proliferation of microvascular 
cells, combined with a relative lack of directional migration of these cells; η = 
hypoxic/necrotic area; shaded structures = préexistent microvessels; white structures = 
newly formed microvessels. 
The finding that glomeruloid MVP can be present around rather than 
within intracerebral metastatic carcinomas 31·59·75 supports the notion that 
there may be something about the brain's microenvironment that inhibits 
the formation of vascular sprouts. Although recent studies show that 
microvascular cells in GBMs express ECM-binding adhesion molecules 
relevant for angiogenesis (especially avß3) 76"78, and indicate that the 
enzymes for proteolytic degradation of perivascular ECM-barriers are 
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available 7982, inadequate production and/or activation of such adhesion 
molecules and proteases cannot be excluded. Furthermore, since in normal 
human brain and in most glial neoplasms ECM proteins such as 
fibronectin, laminin and the different types of collagen are essentially 
confined to the vessel walls 5', a scaffold of complementary matrix 
components for directional migration of microvascular cells may be lacking 
in glial (tumor) tissue. If this interpretation is correct, glomeruloid MVP 
would represent angiogenesis that is incomplete or even "frustrated" 
because of the lack of a supportive ECM in the brain parenchyma. Some 
areas of GBMs do show an increased number of microvessels 8385, in such 
areas the migration of microvascular cells into the glial tumor tissue during 
angiogenesis may have been facilitated by an altered expression of ECM 
components by tumor cells 77·86 89. 
Significance of brain tumor angiogenesis 
Quantitative aspects 
Consideration of the origin of microvessels in a tumor must recognize two 
different populations: a) préexistent host vessels incorporated into the 
tumor tissue and b) microvessels arising from neovascularization due to the 
influence of angiogenic factors 71. Especially in tumors showing diffuse 
infiltrative, rather than expanding, growth, many intratumoral vessels may 
be incorporated préexistent vessels rather than those newly formed by 
angiogenesis ^. Consequently, a high, but normal, microvessel density can 
be expected in a diffuse astrocytoma infiltrating in the abundantly 
vascularized cerebral cortex M-iS. 
While florid MVP in glial tumors suggests a highly vascularized tumor, 
quantitative analysis showed that in areas with florid MVP the number of 
separate vascular structures was often not increased. In other areas, 
however, a very high number of delicate microvessels can be found, 
indicating that here classic angiogenesis with directional growth of 
microvascular sprouts may have occurred 83'85 (fig. 4). Recent studies of 
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astrocytic and other brain tumors described an inverse correlation between 
microvessel density and survival 91,92 and suggested that microvessel 
quantitation in biopsied brain tumors may provide improved prognostic 
information. In a biopsy study of human cortex infiltrated by malignant 
glioma, an increase in vessel density was only found in some cases of 
markedly and completely infiltrated cortex. This angiogenic reaction to 
tumor infiltration was considered as late, slow, and inconstant93. 
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FIG. 4. Computer-assisted analysis of microvascular parameters in GBM showing the two 
forms of angiogenic reaction schematically represented in fig. 3; a,b: very high density of 
delicate microvessels; c,d: glomeruloid MVP; a,c: digitized microscopic image (PAS-
collagen IV staining, original magnification lOOx); b,d: delineation of microvascular 
profiles. See u for image analysis procedure and definitions of microvascular parameters. 
Although the contribution of these different angiogenic reactions to the perfusion of the 
tumor tissue remains to be established, the formation of delicate microvessels may well be 
functionally more important for the survival of tumor tissue than the striking glomeruloid 
MVP illustrated in c,d and in fig. 2. 
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Qualitative aspects. 
The morphological appearance of the tumor vasculature does not allow 
direct judgments concerning the tumor blood flow 71 ,94, and the functional 
contribution of the aberrant, glomeruloid MVP in GBMs is unclear. The 
coexistence of glomeruloid MVP and (sometimes extensive) necrosis in 
GBMs indicates that this angiogenic reaction occurred as a late, secondary 
effect of VEGF production by hypoxic tumor tissue, and that this reaction 
was insufficient or too late to save (part of) the endangered tumor tissue 
from death 9 5 · 9 6 . If the last is true, then the interdiction of glomeruloid 
MVP may have limited therapeutic effect. Even a high number of delicate 
tumor vessels does not guarantee a high nutritive flow, as is illustrated by 
the fact that in human gliomas xenografted in nude mice the perfused 
fraction of tumor vessels ranged from 20% to 85% 97. 
Interestingly, angiogenesis/MVP in GBMs does not seem to substantially 
contribute to extracranial metastatic spread, since extracranial metastases of 
GBMs are very rare. The occurrence of such extracranial metastases may 
be related to neurosurgical procedures (craniotomy, placement of 
ventriculo-peritoneal shunt) 98. Various hypotheses were generated to 
explain the lack of extracranial dissemination of glial tumors, including 
short survival of patients, elimination of metastatic glioma cells because of 
immunogenicity, differences in extracellular environment between brain 
and other tissues, and lack of relevant adhesion molecules on glioma cells 
53 54.99 ιοί Furthermore, in some tumor systems production of anti-
angiogenic factors by the primary tumor may keep extracranial^ 
disseminated tumor cells in a dormant state 102. 
Therapeutic opportunities 
Anti-angiogenic therapy 
Folkman in 1971 hypothesized that anti-angiogenic treatment is a potential 
therapy for solid tumors u 6 . The proliferation rate of ECs in tumors 
largely exceeds that in most adult tissues, this difference offers a target for 
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anti-cancer therapy '6103 Based on new insights into the mechanisms of 
angiogenesis, novel therapeutic approaches targeting this process have been 
developed A104 '05 Numerous compounds display inhibition of angiogenesis 
under experimental conditions While the mechanism of action of some of 
these compounds is not yet established, other factors interfere with one or 
more of the following steps in the angiogenic process release of 
angiogenic factors, binding of angiogenic factors to their receptors, 
degradation of basement membrane, migration and/or proliferation of ECs, 
and three-dimensional organization of microvessels IW l05 Some anti-
angiogenic agents are now being studied in phase 1 and 2 clinical trials for 
solid tumors like breast, colon, lung, and prostate cancer 4 It remains to 
be seen whether the anticipated beneficial anti-tumor effects are 
accompanied by unwanted compromises in wound healing, endometrial 
proliferation, etc 105 
The efficacy of anti-angiogenic tumor therapy will be determined by the 
amount of tumor tissue that is dependent on neovascularization for 
sustained growth and the level of functional neovascularization in these 
areas While solid, expanding brain tumors require ingrowth of blood 
vessels for survival and growth, tumor cells infiltrating in the well 
vascularized brain tissue will encounter nutrient supplies at frequent 
intervals as they advance 1A 9i m 107 At first, such infiltrative tumors may 
escape the requirements of neovascularization and be resistant to anti-
angiogenic treatment When, however, in a certain area (e g during 
malignant progression) the amount of infiltrating tumor cells surpasses a 
critical number or the metabolic demands of the tumor cells increase, 
ultimately hypoxia will occur In this tumor area the cells will become 
dependent on angiogenesis for survival and growth m I07 In the interim, 
other areas of the same tumor (e g less malignant or less densely 
populated areas in the critical tumor periphery) may not be angiogenesis-
dependent 
Brain tumors 
Inhibition of tumor angiogenesis forms an exciting new approach to control 
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tumor growth, but its applicability for infiltrating human brain tumors such 
as GBMs remains thus to be established and there are anatomic reasons in 
GBMs to be cautious in ones enthusiasm The diffuse infiltrative growth of 
many glial neoplasms could very well hamper the success of anti-
angiogenic therapy Glomeruloid MVP in such tumors indicates that 
angiogenic activity (and hypoxia) was present, but the functional 
significance and thus the effect of inhibiting this aberrant MVP could be 
limited The efficiency of anti-angiogenic therapy may be determined by 
the extent of the formation of delicate microvascular sprouts rather than by 
the degree of glomeruloid MVP in these tumors Animal studies showing 
that the growth of glioma xenografts can be inhibited by anti-angiogenic 
treatment l013 should be interpreted with caution While some studies 
describe extensive migration of human glioma cells xenografted in the 
brain of laboratory animals l08 m, these glioma models are generally 
expansive rather than diffusely infiltrative 52 According to the hypothesis 
of Folkman '16 a more solid growth pattern of glioma models implicates an 
increased dependency on angiogenesis compared to the original, diffuse 
infiltrative, human neoplasms 
The question then arises if there are not brain tumors other than GBMs 
where anti-angiogenic therapy might, because of either "cidal" or "static" 
effects, be more effective Meningiomas, meningeal hemangiopericytomas, 
medulloblastomas, hemangioblastomas, and metastatic carcinomas are 
examples of such lesions Meningiomas and hemangiopericytomas form 
solid and expanding masses, implicating that these tumors require ingrowth 
of vessels for sustained growth (fig. 5) Consequently, these tumors may 
be good candidates for anti-angiogenic therapy, albeit a "static" form which 
seeks to stabilize rather than eradicate a mass Hemangiopericytomas are 
notoriously difficult to cure, in this setting a "static" response of a 
recurrent lesion or lesions could be a major therapeutic advance Some 
gliomas also show an expanding, rather than infiltrative growth pattern, 
and local recurrence of a mass rather than diffuse infiltration is the 
common expression of treatment failure Such lesions include the richly 
vascularized pilocytic astrocytomas (especially the chiasmatic and 
hypothalamic types) and ependymomas These should in our opinion be 
considered as potential targets for anti-angiogenic therapy 
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FIG. 5. a. Subtraction angiography of internal carotid artery demonstrating extensive 
vascularization of a frontal meningioma and its dependence on external vessels for its 
supply; part of this tumor (indicated by asterisk) was fed by vessels from the middle 
meningeal artery; b. immuno-light microscopic demonstration of very high microvascular 
density in meningioma using an endothelial marker (CD34/QBend staining, original 
magnification x200). 
Perspectives and conclusions 
The hypothesis of Folkman that solid tumors are angiogenesis-dependent 
has stimulated an enormous amount of research that has increased our 
awareness and knowledge about the angiogenic process and how it might 
relate to brain tumor therapy. MVP in GBMs may provide a target for 
interference with tumor angiogenesis and growth. However, the 
applicability of anti-angiogenic therapy for human brain tumors is not yet 
established. The results of anti-angiogenic treatment of glioma-xenografts 
in animal models should be interpreted with caution, because the growth of 
these xenografts is often dissimilar from their human counterparts. The 
diffuse infiltrative growth of most human gliomas could hamper the succes 
of anti-angiogenic therapy. Brain tumors with a more solid, expanding 
growth pattern may be additional neoplasms which are candidates for such 
therapy. 
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Summary 
Tumor cells are dependent on the vasculature for their supply of oxygen 
and nutrients and removal of waste products Solid tumors therefore need 
to induce angiogenesis to meet the metabolic demands of a growing 
population of tumor cells Already in 1971 Folkman hypothesized that anti-
angiogenic treatment is a potential therapy for these tumors This 
hypothesis has stimulated an enormous amount of research that drastically 
increased our knowledge about the angiogenic process Angiogenesis is a 
complex process, including multiple coordinated steps, such as production 
and release of angiogenic factors, directional migration and proliferation of 
microvascular cells, proteolytic degradation of extracellular matrix (ECM) 
barriers, and the composition of new vessels Based on new insights into 
the mechanisms of angiogenesis, novel therapeutic approaches targeting this 
process have been developed, and some anti-angiogenic agents are now 
being studied in phase 1 and 2 clinical trials 
The most common primary brain tumors in adults are diffuse astrocytic 
neoplasms Because of their infiltrative growth in the préexistent brain 
tissue, these tumors are very difficult to treat by conventional therapies 
The most frequent and most malignant form of these tumors, glioblastoma 
multiforme (GBM), often shows striking, glomeruloid microvascular 
proliferation (MVP) Because of this MVP, GBMs have become especially 
strong candidates for anti-angiogenic treatment However, the 
morphological appearance of the tumor vasculature does not allow direct 
judgments concerning the tumor blood flow The aberrant architecture of 
glomeruloid MVP and its paradoxical coexistence with (sometimes 
extensive) foci of necrosis suggest that its contribution to the viability of 
the tumor tissue may be limited The efficacy of anti-angiogenic treatment 
may rather be determined by the extent of classic angiogenesis as 
manifested by the formation of delicate microvascular sprouts 
The computerized, quantitative analysis described in chapter 2 illustrates 
the striking heterogeneity of the microvasculature in post-mortem, "whole 
tumor sections" of GBMs While some tumor areas show glomeruloid 
MVP, in other areas a very high number of delicate microvessels is found, 
indicating that here classic angiogenesis did occur In many other vital 
tumor areas, however, the microvascular architecture is not substantially 
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different from that of normal brain tissue, such regions are probably not 
overtly angiogenesis dependent and/or amenable to anti-angiogenic therapy. 
In the study described in chapter 3 a similar method is applied to quantify 
the microvascular changes in biopsies of supratentorial diffuse astrocytic 
neoplasms with increasing grade of malignancy (astrocytomas (As), 
anaplastic astrocytomas (AAs), and GBMs). This study corroborates the 
findings of chapter 2 and shows that not only glomeruloid MVP, but also 
classic angiogenesis occurs mainly and only locally in GBMs. Also in As 
and AAs some new delicate microvessels may be formed, but this 
angiogenic reaction is often difficult to distinguish from tumor infiltration 
in the abundantly vascularized cerebral grey matter. 
Florid MVP in GBMs has long been considered as proliferation of 
endothelial cells (ECs). In chapter 4 and 5 we demonstrate at both the 
light- and electron microscopic level the early and extensive contribution of 
pericytes/vascular smooth muscle cells (VSMCs) to this angiogenic proces. 
While pericytes can be considered as multipotential, microvascular 
representatives of VSMCs, the role of these cells during angiogenesis is 
still largely obscure. The study described in chapter 6 demonstrates the 
expression of the ectoenzyme aminopeptidase A as recognized by the 
monoclonal antibody RC38 on activated pericytes (but not on VSMCs of 
larger blood vessels) in tissues showing neovascularization. This finding 
suggests that pericytes play a role in the metabolism of biologically active 
oligopeptides during angiogenesis. 
The architecture of glomeruloid MVP can be explained by proliferation of 
microvascular cells, combined with a relative lack of directional migration 
into the glial (tumor) tissue, resulting in the formation of a coiled mass of 
capillaries instead of delicate vascular sprouts. The formation of functional 
vascular sprouts during classic angiogenesis depends on directional 
migration of microvascular cells in the surrounding tissue. The ability of 
microvascular cells to exert adhesive interactions with the extracellular 
matrix of the surrounding tissue plays an important role in the directional 
migration of these cells. Most of the identified ECM-receptors on ECs are 
of the integrin type. In chapter 7 we demonstrate that at least part of the 
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glomeruloid MVP in GBMs expresses integrins relevant for invasive 
angiogenesis, but in large areas of the surrounding brain parenchyma a 
scaffold of the investigated complementary ECM ligands is lacking. While 
inadequate interactions between microvascular integrins and the 
surrounding glial ECM may contribute to the aberrant, glomeruloid 
angiogenic reaction in GBMs, the angiogenic process is too complex to 
draw simple conclusions. 
In chapter 8 the pathobiological and clinical aspects of angiogenesis in 
human brain tumors are reviewed. Apart from summarizing the aspects 
covered in the previous chapters of this thesis, it is stressed that the 
efficacy of anti-angiogenic tumor therapy will be determined by the amount 
of tumor tissue that is dependent on neovascularization for sustained 
growth and the level of functional neovascularization in these areas. The 
diffuse infiltrative growth of many glial neoplasms could very well hamper 
the success of anti-angiogenic therapy, since préexistent vessels may suffice 
to provide many tumor cells with much of their blood supply, particularly 
in the critical peripheral infiltrative margins. The efficiency of anti-
angiogenic therapy may be determined by the extent of the formation of 
delicate microvascular sprouts rather than by the degree of the aberrant, 
glomeruloid MVP in these tumors. In diffuse astrocytic neoplasms both 
angiogenic reactions are mainly and only locally present in GBMs. Even if 
anti-angiogenic therapy ultimately has a role in these neoplasms, there are 
a host of other intracranial neoplasms (e.g. meningiomas, hemangio-
pericytomas) whose discrete architecture might make them more attractive 
candidates for anti-angiogenic therapy. 
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Samenvatting 
Tumorcellen zijn aangewezen op bloedvaten voor de aanvoer van zuurstof 
en voedingsstoffen en de afvoer van afvalprodukten. Solide tumoren dienen 
angiogenese te induceren om in de metabole behoefte van de groeiende 
populatie van tumorcellen te voorzien. Reeds in 1971 veronderstelde 
Folkman dat dergelijke tumoren gevoelig zijn voor anti-angiogene therapie. 
Deze hypothese genereerde een grote hoeveelheid wetenschappelijk 
onderzoek. Door dit onderzoek is inmiddels veel kennis vergaard over het 
proces van angiogenese. Angiogenese is een complex proces met meerdere, 
gecoördineerde stappen, zoals productie en afgifte van angiogene factoren, 
gerichte migratie en proliferatie van microvasculaire cellen, afbraak van 
barrieres van extracellulaire matrix (ECM) eiwitten, en de assemblage van 
nieuwe bloedvaten. Gebaseerd op deze kennis van het angiogene proces 
zijn nieuwe benaderingen ontwikkeld om dit proces te beïnvloeden, en 
inmiddels worden al enkele anti-angiogene middelen getest in klinische 
studies. 
De meest frequent voorkomende, primaire hersentumoren bij volwassenen 
zijn diffuse astrocytaire tumoren. Deze gezwellen zijn vanwege hun 
uitgebreide infiltratieve groei in het pre-existente hersenweefsel maar in 
zeer beperkte mate te behandelen met conventionele behandelingsmethoden. 
Van deze tumoren komt de meest kwaadaardige vorm, het glioblastoma 
multiforme (GBM), het vaakst voor. GBMs tonen dikwijls opvallende, 
glomeruloide microvasculaire proliferatie (MVP). Vanwege deze MVP 
wordt vaak gesteld dat GBMs bij uitstek kandidaten zijn voor anti-
angiogene behandeling. De morfologie van de microvasculatuur in een 
tumor zegt evenwel niet direkt iets over de bloedvoorziening van de tumor. 
De afwijkende architectuur van glomeruloide MVP en de topografische 
relatie van deze MVP met (soms uitgebreide) necrosehaarden suggereren 
een beperkte rol bij het vitaal houden van het tumorweefsel. Het is goed 
mogelijk dat, meer dan glomeruloide MVP, de mate van klassieke 
angiogenese met vorming van delicate bloedvaatjes in diffuse astrocytaire 
tumoren bepalend is voor hun gevoeligheid voor anti-angiogene therapie. 
In hoofdstuk 2 wordt een gecomputeriseerde, kwantitatieve analyse 
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beschreven van de microvasculatuur m "whole tumor" coupes van na de 
dood verkregen materiaal van GBMs Deze studie illustreert een zeer 
uitgesproken heterogeniteit van de microvasculatuur in GBMs Sommige 
delen tonen glomeruloide MVP, in andere delen wordt een zeer groot 
aantal delicate bloedvaatjes aangetroffen In veel gebieden verschilt de 
microvasculatuur in GBMs echter niet wezenlijk van die in normaal 
hersenweefsel, deze gebieden lijken niet direkt afhankelijk van angiogenese 
en derhalve ook niet direkt gevoelig voor anti-angiogene therapie 
In hoofdstuk 3 wordt een gelijksoortige methode gebruikt om de 
veranderingen in de microvasculatuur te kwantificeren in biopten van 
supratentonele, diffuse astrocytaire tumoren met oplopende 
maligniteitsgraad astrocytomen (As), anaplastische astrocytomen (AAs), en 
GBMs Dit onderzoek bevestigt de resultaten van het onderzoek beschreven 
in hoofdstuk 2 en toont verder aan dat niet alleen glomeruloide MVP, maar 
ook klassieke angiogenese vooral en dan slechts locaal voorkomt in GBMs 
In As en AAs worden mogelijk ook enige nieuwe, delicate bloedvaatjes 
gevormd, doch in dit onderzoek is een dergelijke angiogene reactie vaak 
moeilijk te onderscheiden van tumoreuze infiltratie in de rijkelijk 
gevasculanseerde, cerebrale grijze stof 
Floride MVP in GBMs wordt sinds lang beschouwd als proliferatie van 
endotheelcellen (ECs) Het licht- en electronen-microscopisch onderzoek 
beschreven in hoofdstuk 4 en 5 toont evenwel een vroege en uitgebreide 
bijdrage van pencyten/vasculaire gladde spiercellen aan Pencyten kunnen 
worden beschouwd als de microvasculaire vorm van vasculaire gladde 
spiercellen, de rol van deze cellen in het angiogene proces is nog niet 
duidelijk De studie beschreven in hoofdstuk 6 demonstreert op 
geactiveerde pencyten (maar niet op vasculaire gladde spiercellen) in 
weefsels met neovasculansatie de expressie van het ecto-enzym 
aminopeptidase A zoals dat wordt herkend door het monoclonale 
antilichaam RC38 Deze bevinding suggereert dat tijdens het angiogene 
proces pencyten een rol spelen bij het metabolisme van biologisch actieve 
Oligopeptiden 
De architectuur van glomeruloide MVP kan worden begrepen als 
proliferatie van microvasculaire cellen, gecombineerd met een relatief 
gebrek aan gerichte migratie van deze cellen m het omgevende gliale 
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(tumor) weefsel, resulterend in een sterk gekronkelde kluwen van 
capillairen in plaats van het uitspruiten van delicate vaatstructuren Voor de 
vorming van deze delicate bloedvaatjes in het kader van een klassieke 
angiogene reactie is gerichte migratie van microvasculaire cellen in het 
omgevende weefsel noodzakelijk Dergelijke gerichte migratie van 
microvasculaire cellen wordt in belangrijke mate bepaald door het 
vermogen van deze cellen om adhesie aan te gaan met de ECM van het 
omgevend weefsel Op ECs zijn de meeste geïdentificeerde receptoren voor 
ECM-componenten van het integrine type De studie in hoofdstuk 7 laat 
zien dat op in ieder geval een deel van de glomeruloide MVP in GBMs 
integnnes tot expressie worden gebracht die relevant zijn voor "invasieve" 
angiogenese, maar dat in grote gebieden van het omgevend 
hersenparenchym de onderzochte, complementaire ECM-componenten 
ontbreken Inadequate interacties tussen microvasculaire integnnes and de 
omgevende, gliale ECM zouden zo kunnen leiden tot afwijkende, 
glomeruloide MVP, maar het angiogene proces is te complex om op basis 
van deze studie eenvoudige conclusies te trekken 
In hoofdstuk 8 wordt een overzicht gegeven van de pathobiologische en 
klinische aspecten van angiogenese in humane hersentumoren Naast 
aspecten die aan de orde zijn gekomen in voorafgaande hoofdstukken wordt 
benadrukt dat het effect van anti-angiogene behandeling van tumoren 
bepaald wordt door 1) de hoeveelheid tumorweefsel die voor verdere groei 
afhankelijk is van de vorming van nieuwe bloedvaatjes en 2) de mate 
waarin functionele angiogenese in dergelijke gebieden optreedt De diffuse, 
infiltratieve groei van veel gliomen kan het effect van anti-angiogene 
therapie erg belemmeren, daar in principe in dergelijke tumoren (in het 
bijzonder in de periferie) veel tumorcellen gebruik kunnen maken van pre-
existente bloedvaten Verder is het goed voorstelbaar dat de gevoeligheid 
van deze tumoren voor anti-angiogene behandeling meer bepaald wordt 
door de mate van klassieke angiogenese dan door het optreden van de 
afwijkende, glomeruloide MVP In diffuse astrocytaire tumoren worden 
beide angiogene reacties vooral en dan slechts plaatselijk gevonden in 
GBMs Hoewel een rol voor anti-angiogene therapie bij de behandeling van 
deze diffuus infiltrerende tumoren niet is uitgesloten lijken andere 
intracraniele tumoren met een meer solide groeiwijze (bijvoorbeeld 
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meningiomen, hemangiopericytomen) betere kandidaten voor zo'n 
behandeling. 
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Stellingen 
behorend bij het proefschrift 
Angiogenesis in brain tumors; 
pathobiological and clinical aspects 
Pieter Wesseling 
Nijmegen, 16 mei 1997 
1. If "anti-angiogenesis" is not possible, or even if the concept is 
wrong, the careful exploration of its consequences may reveal 
something fundamental about the behavior of tumor cells growing 
in a packed population in vivo. 
Folkman J. N Engl J Med (1971) 285:1182-1186. 
2. Het effect van anti-angiogene behandeling van tumoren wordt 
bepaald door de hoeveelheid tumorweefsel die voor verdere groei 
afhankelijk is van angiogenese en de mate waarin functionele 
angiogenese in dergelijke gebieden optreedt. 
Dit proefschrift. 
3. Consideration of the origin of microvessels in a tumor must 
recognize two different populations: a) pre-existent host vessels 
incorporated into the tumor tissue and b) microvessels arising from 
neovascularization due to the influence of angiogenic factors. 
Vaupel P, et al., Cancer Res (1989) 49:6449-6465. 
4. Anders dan bij tumoren met een expansieve groeiwijze kunnen in 
tumoren met een diffuus infiltrerende groeiwijze veel bloedvaatjes 
preexistente bloedvaatjes zijn. 
Dit proefschrift. 
5. De architectuur van de tumorvasculatuur zegt niet direkt iets over 
de perfusie van het tumorweefsel; de perfusie van tumorweefsel 
zegt niet direkt iets over de oxygenatie van dit weefsel. 
Dit proefschrift en Helmlinger G, et al, Nature Med (1997) 3:177-
182. 
6. The rational development of therapy for a disease depends critically 
on knowledge about its pathogenesis. In the absence of such 
insight, physicians are vulnerable to the prevailing winds of 
opinion and practice, each liable to shift from one moment to 
another. 
Rizzo WB. N Engl J Med (1993) 329:801-802. 
7. The most important lesson we have to learn ... is the extraordinary 
capacity of the (medical) profession for self-delusion. 
Editorial. Lancet (1993) 341:343-344. 
8. Unless expert neuropathologists reach greater consensus than 
currently exists among them in their diagnoses and classifications 
of CNS tumors, their image as bearers of the gold standard of 
diagnosis will be considerably tarnished. 
Rorke LB. Cancer (1997) 79:665-667 
9. If the brain would be so simple that we could understand it, we 
would be so simple that we couldn't. 
Anonymus. 
10. 1 Olf is the air pollution from one standard person, i.e. from one 
average adult working in an office, sedentary, and in thermal 
comfort with a hygienic standard equivalent to 0.7 bath/day. 
McCormick J. Lancet (1993) 341:1126-1127. 
11. Given two graphics that display identical information, the better 
graphic uses less ink. 
Jolley D. Lancet (1993) 342:27-29. 
12. Om het geweld op het voetbalveld te beteugelen verdient het 
overweging de strafschop in letterlijke zin in te voeren. 
13. Vanuit het oogpunt van doelgerichtheid en doelmatigheid verdient 
het aanbeveling om Faculteit der Medische Wetenschappen en 
Academisch Ziekenhuis samen te voegen tot één Universitair 
Medisch Centrum. 
14. Het intensief beoefenen van de pathologie geeft een verhoogde kans 
op de ontwikkeling van bijziendheid in zowel letterlijke als figuur-
lijke zin. 
Eigen waarneming. 
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